Materiały źródłowe

• #1 Chondrosarcoma: A Clinical Review

  https://pmc.ncbi.nlm.nih.gov/articles/PMC10095313/

  Chondrosarcomas are considered the second most common sarcoma of bone following osteosarcoma. Chondrosarcoma accounts for 2030% of all skeletal sarcomas and have an estimated incidence of 1 in 200,000 per year in the United States. Recent literature has suggested that rates of chondrosarcoma are increasing and chondrosarcoma is now considered the most common primary bone malignancy in several countries due to the increase in ACTs diagnosed incidentally. Chondrosarcoma has a mean age of presentation of 51, with over 70% of patients over the age of 40 at the time of diagnosis. Notably, a rare subtype, mesenchymal chondrosarcoma, presents at a much younger age, with a peak incidence in the second and third decades of life. Chondrosarcoma demonstrates a slight predilection towards males; however, this varies by subtype.

• #2 Chondrosarcoma – UpToDate

  https://www.uptodate.com/contents/chondrosarcoma

  Chondrosarcomas are the third most common primary malignancy of bone after myeloma and osteosarcoma. They account for 20 to 27 percent of primary malignant osseous neoplasms. […] Conventional chondrosarcomas comprise a majority (90 percent) of all chondrosarcomas. […] High-grade chondrosarcomas are rare. These high-grade chondrosarcomas, along with other ultrarare variants, comprise approximately 5 to 10 percent of all chondrosarcomas. […] Histologic grade is one of the most important indicators of clinical behavior and prognosis.

• #3 Treatment method and prognostic factors of chondrosarcoma: based on Surveillance, Epidemiology, and End Results (SEER) database – Hua – Translational Cancer Research

  https://tcr.amegroups.org/article/view/41253/html

  Chondrosarcoma is a malignant tumor originating from cartilage tissue. It is the second most malignant bone tumor, accounting for about 10% to 15% of all primary bone tumors. […] So far, there have been no reports of large-scale clinical statistics on the relationship between non-surgical treatment and prognosis in patients with chondrosarcoma. […] The annual incidence of about 200,000 people, accounting for about 20% of bone malignant tumor in the United States. […] In order to solve the problem of insufficient clinical data, we collected information on patients with chondrosarcoma from the Surveillance, Epidemiology, and End Results (SEER) database managed by the National Cancer Institute. […] This study found that although non-surgical treatment of chondrosarcoma has made great progress, at present, it is still not considered that non-surgical treatment can significantly improve the prognosis. There are many factors affecting the prognosis of chondrosarcoma, including age, primary site, histological type, grade, tumor size, distant metastasis and treatment method. […] The results showed age, primary site, histological type, grade, tumor size, metastasis, and treatment method were independent factors affecting ACM and CSSM.

• #4 Chondrosarcoma: Practice Essentials, Pathophysiology, Epidemiology

  https://emedicine.medscape.com/article/1258236-overview

  Conventional central chondrosarcomas account for nearly 80-90% of all chondrosarcomas and 20-27% of all primary bone sarcomas. They demonstrate a predilection for the axial skeleton. Rates of involvement are as follows: Pelvis and ribs, 45%; Ilium, 20%; Femur, 15%; Humerus, 10%; Others, 10%. The spine and the craniofacial bones are rarely involved. […] Chondrosarcomas are considerably rarer in children and adolescents than in adults.

• #5 Chondrosarcoma epidemiology and demographics – wikidoc

  https://www.wikidoc.org/index.php/Chondrosarcoma_epidemiology_and_demographics

  Chondrosarcoma is the second most common malignant primary tumor of bone. It is most frequently diagnosed in patients in their 4th and 5th decades of life. Men are slightly more affected by chondrosarcoma than women. There is no racial predilection to chondrosarcoma. […] Chondrosarcoma is the second most common primary bone sarcoma. The incidence of chondrosarcoma is approximately 1 per 100,000 individuals worldwide. […] Chondrosarcoma is most frequently diagnosed in patients in their 4th and 5th decades of life. The average age at presentation is 51 years. […] There is no racial predilection to chondrosarcoma. […] Chondrosarcoma affects men and women almost equally with slight male predominance. Exception to this is the clear cell sub-type which has significant male preponderance. The male to female ratio is almost 1:1 except for clear cell chondrosarcoma it is 2.4:1.

• #6 Chondrosarcoma – NCI

  https://www.cancer.gov/pediatric-adult-rare-tumor/rare-tumors/rare-bone-tumors/chondrosarcoma

  CS is a rare type of bone tumor and affects 1 person per 200,000 per year in the US. It is more common in adults. […] Doctors estimate CS survival rates by how groups of people with CS have done in the past. Because there are so few CS patients, these rates may not be very accurate. […] The average 5-year survival rate for patients with CS is different depending on the subtype of CS the patient has. Different types of CS may grow more quickly or come back after the tumor is removed. In cases where the tumor grows back, called recurrence, or has spread to other parts of the body, the survival rate may be lower.

• #7 Chondrosarcoma: A Clinical Review

  https://pmc.ncbi.nlm.nih.gov/articles/PMC10095313/

  Chondrosarcomas are considered the second most common sarcoma of bone following osteosarcoma. Chondrosarcoma accounts for 2030% of all skeletal sarcomas and have an estimated incidence of 1 in 200,000 per year in the United States. Recent literature has suggested that rates of chondrosarcoma are increasing and chondrosarcoma is now considered the most common primary bone malignancy in several countries due to the increase in ACTs diagnosed incidentally. Chondrosarcoma has a mean age of presentation of 51, with over 70% of patients over the age of 40 at the time of diagnosis. Notably, a rare subtype, mesenchymal chondrosarcoma, presents at a much younger age, with a peak incidence in the second and third decades of life. Chondrosarcoma demonstrates a slight predilection towards males; however, this varies by subtype.

• #8 The Epidemiology of Chondrosarcoma in Iran Based on Iran National Cancer Registry

  https://brieflands.com/articles/ijcm-119308

  The age-specific incidence rate of chondrosarcoma and its 3 more prevalent subtypes, conventional, myxoid, and mesenchymal, per million person-years among the Iranian population are shown in Table 3. […] The ASIR of chondrosarcoma varies between 1 and 3 per million people in different countries. […] The ASIR of chondrosarcoma was slightly higher in males (1.73 in 1 million people) than females (1.27 in 1 million people). […] The mean age of patients in our study was 44.08 at the time of diagnosis, which is considerably less compared to studies in Norway, the USA, and the Netherlands, wherein the mean age at the time of diagnosis was above 50 years. […] Higher mortality of chondrosarcoma in Iran indicates a need for better case-finding and follow-up of patients with chondrosarcoma in Iran as timely diagnosis and proper care may improve the patient’s outcomes and survival.

• #9 Chondrosarcoma | Bone Cancer Research Trust

  https://www.bcrt.org.uk/information/information-by-type/chondrosarcoma/

  Chondrosarcoma is the most common primary bone cancer in adulthood, and the second most common primary bone cancer overall. It makes up around 25% of all malignant bone cancer cases. […] In the UK there are around 190 new cases of chondrosarcoma diagnosed each year. In The Republic of Ireland there are around 12 new cases of chondrosarcoma diagnosed each year. […] The incidence rate in England is around 2.9 people affected per 1 million people of the population. […] Chondrosarcoma is the most common form of primary bone cancer affecting all age groups. […] 80% of cases are in people aged 40 years or older.

• #10 Epidemiology and Survivorship of Chondrosarcoma in the United States: An Analysis of the National Cancer Database | MDedge

  https://community.the-hospitalist.org/content/epidemiology-and-survivorship-chondrosarcoma-united-states-analysis-national-cancer-database

  Chondrosarcoma (CHS) is the second most common primary malignant solid bone tumor. […] This study summarizes descriptive epidemiologic and prognostic characteristics associated with CHS patients utilizing the National Cancer Database (NCDB). […] We identified 6,559 patients with CHS of the bone, joints, and/or articular cartilage in the NCDB from 2004-2015. […] Median age at diagnosis was 53 years. 53.3% of cases were in males, and 86.4% were in white patients. […] The most common NCDB analytic stage at presentation was stage I (60.5%). […] Overall probability of 5-year survival was 74.4%. […] The dedifferentiated subtype of CHS had the poorest 5-year survival (25.4%), while juxtacortical had the highest (93.4%). […] This study found CHS was most common in white patients, had a median age at diagnosis of 53 years, and was most frequently found in lower limb long bones and associated joints. […] The 5-year survival was much worse at stage IV compared to stages I, II, and III, as well as in dedifferentiated and mesenchymal tumor subtypes compared to conventional or other types of CHS. […] In high grade tumors, perioperative chemotherapy did not improve survival compared to surgery alone.

• #11 Chondrosarcoma – Epidemiology Forecast – 2032

  https://www.researchandmarkets.com/reports/5238582/chondrosarcoma-epidemiology-forecast-2032?srsltid=AfmBOopTFVTNWFjFLez9dKypoiD2kbfp8ntI3DNdLaAz8XD0Ukc_K-r_

  Chondrosarcoma is the most common primary bone cancer in adulthood and the second most common primary bone cancer overall, making up around 25% of all malignant bone cancer cases. […] The total incident cases of chondrosarcoma in the 7MM comprised approximately 2,300 cases in 2022 and are projected to increase during the forecasted period. […] The total number of incident cases of chondrosarcoma in the United States was around 1,371 cases in 2022. […] The United States contributed to the largest incident population of chondrosarcoma, acquiring ~59% of the 7MM in 2022. […] According to the estimates, in the United States, there were around 485, 584, 177, and 125 cases of Grade I, II, III, and IV, respectively, in 2022. […] Among the stage-specific rates of conventional chondrosarcoma, localized conventional chondrosarcoma accounted for approximately 75% of the patient share, while the rest of them were metastatic in nature. […] When it comes to disease progression, the rate is quite high in patients with high-grade conventional chondrosarcoma as compared to the ones with low-grade conventional chondrosarcoma.

• #12 Chondrosarcoma Market Outlook to 2032: Emerging Therapies and Market Access Drive Growth in the 7MM, Addressing Unmet Needs in Rare Bone Cancer Treatment – ResearchAndMarkets.com

  https://www.businesswire.com/news/home/20230809811627/en/Chondrosarcoma-Market-Outlook-to-2032-Emerging-Therapies-and-Market-Access-Drive-Growth-in-the-7MM-Addressing-Unmet-Needs-in-Rare-Bone-Cancer-Treatment—ResearchAndMarkets.com

  Chondrosarcoma Epidemiology: The total incident cases of chondrosarcoma in the 7MM were approximately 2,331 cases in 2022 and are projected to increase during the forecast period. The United States accounted for the largest incident population of chondrosarcoma, followed by EU4 countries (Germany, France, Italy, and Spain) and Japan. […] Current Treatment Patterns: Surgical treatment remains the mainstay for both appendicular and axial chondrosarcomas. Chemotherapy and radiation are generally ineffective in conventional chondrosarcoma, with limited standard systemic therapy options. […] Market Outlook: The total market size of chondrosarcoma in the 7MM is approximately USD 9 million in 2022 and is projected to increase during the forecast period at a CAGR of 24.8% due to increasing awareness of the disease and the launch of emerging therapies.

• #13 Chondrosarcoma – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK538132/

  Chondrosarcoma is a tumor of adulthood and older age. The majority of patients are older than 50 years of age at diagnosis, with a slight male predominance. The most common locations of involvement of chondrosarcoma include the bones of the axial skeleton (pelvis, scapula, sternum, and ribs) followed by the proximal femur and proximal humerus. Involvement of the hands and feet is rare. […] Primary central chondrosarcoma is the third most common primary malignancy of bone after myeloma and osteosarcoma.

• #14 Chondrosarcoma: A Clinical Review

  https://pmc.ncbi.nlm.nih.gov/articles/PMC10095313/

  Chondrosarcomas are considered the second most common sarcoma of bone following osteosarcoma. Chondrosarcoma accounts for 2030% of all skeletal sarcomas and have an estimated incidence of 1 in 200,000 per year in the United States. Recent literature has suggested that rates of chondrosarcoma are increasing and chondrosarcoma is now considered the most common primary bone malignancy in several countries due to the increase in ACTs diagnosed incidentally. Chondrosarcoma has a mean age of presentation of 51, with over 70% of patients over the age of 40 at the time of diagnosis. Notably, a rare subtype, mesenchymal chondrosarcoma, presents at a much younger age, with a peak incidence in the second and third decades of life. Chondrosarcoma demonstrates a slight predilection towards males; however, this varies by subtype.

• #15 Chondrosarcoma: A Clinical Review

  https://www.mdpi.com/2077-0383/12/7/2506

  Chondrosarcomas are considered the second most common sarcoma of bone following osteosarcoma. Chondrosarcoma accounts for 20–30% of all skeletal sarcomas and have an estimated incidence of 1 in 200,000 per year in the United States. Recent literature has suggested that rates of chondrosarcoma are increasing and chondrosarcoma is now considered the most common primary bone malignancy in several countries due to the increase in ACTs diagnosed incidentally. Chondrosarcoma has a mean age of presentation of 51, with over 70% of patients over the age of 40 at the time of diagnosis. Notably, a rare subtype, mesenchymal chondrosarcoma, presents at a much younger age, with a peak incidence in the second and third decades of life. Chondrosarcoma demonstrates a slight predilection towards males; however, this varies by subtype.

• #16 Epidemiology and Survivorship of Chondrosarcoma in the United States: An Analysis of the National Cancer Database | MDedge

  https://www.mdedge.com/fedprac/avaho/article/175095/mixed-topics/epidemiology-and-survivorship-chondrosarcoma-united-states

  Chondrosarcoma (CHS) is the second most common primary malignant solid bone tumor. This study summarizes descriptive epidemiologic and prognostic characteristics associated with CHS patients utilizing the National Cancer Database (NCDB). We identified 6,559 patients with CHS of the bone, joints, and/or articular cartilage in the NCDB from 2004-2015. Median age at diagnosis was 53 years. 53.3% of cases were in males, and 86.4% were in white patients. The most common NCDB analytic stage at presentation was stage I (60.5%). Overall probability of 5-year survival was 74.4%. The 5-year survival was much worse at stage IV compared to stages I, II, and III, as well as in dedifferentiated and mesenchymal tumor subtypes compared to conventional or other types of CHS. […] This study found CHS was most common in white patients, had a median age at diagnosis of 53 years, and was most frequently found in lower limb long bones and associated joints. In high grade tumors, perioperative chemotherapy did not improve survival compared to surgery alone.

• #17 Chondrosarcoma: A Clinical Review

  https://pmc.ncbi.nlm.nih.gov/articles/PMC10095313/

  Chondrosarcomas are considered the second most common sarcoma of bone following osteosarcoma. Chondrosarcoma accounts for 2030% of all skeletal sarcomas and have an estimated incidence of 1 in 200,000 per year in the United States. Recent literature has suggested that rates of chondrosarcoma are increasing and chondrosarcoma is now considered the most common primary bone malignancy in several countries due to the increase in ACTs diagnosed incidentally. Chondrosarcoma has a mean age of presentation of 51, with over 70% of patients over the age of 40 at the time of diagnosis. Notably, a rare subtype, mesenchymal chondrosarcoma, presents at a much younger age, with a peak incidence in the second and third decades of life. Chondrosarcoma demonstrates a slight predilection towards males; however, this varies by subtype.

• #18 Mesenchymal chondrosarcoma | Radiology Reference Article | Radiopaedia.org

  https://radiopaedia.org/articles/mesenchymal-chondrosarcoma?lang=us

  Mesenchymal chondrosarcomas are rare tumors and make up for ~2-4% of all chondrosarcomas. They occur in a wide age range and peak in the second and third decades of life. They are slightly more common in men. […] Mesenchymal chondrosarcomas are aggressive neoplasms with 5-year and 10-year survival rates ranging around ~60% and ~40%. Management includes complete resection combined with chemotherapy or radiotherapy. Young adults and children tend to have better outcomes as well as a craniofacial origin, whereas an axial origin and distant metastases at initial presentation are associated with a poorer prognosis. […] Complications include local recurrences and distant metastases, the latter can occur as late as 20 years after an initial presentation.

• #19 Periosteal Chondrosarcoma – SFA

  https://curesarcoma.org/sarcoma-subtypes/periosteal-chondrosarcoma/

  Periosteal chondrosarcoma is a rare chondrosarcoma subtype, representing about 2.5% of all chondrosarcomas. It has a peak incidence in the third decade of life, with a wide age range (9–79 years) and a male predominance. […] Periosteal chondrosarcomas have a relatively low metastatic rate (5–12.2%), with metastases especially involving the lungs and rarely the lymph nodes. Histological grading does not predict outcome.

• #20 Chondrosarcoma – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK538132/

  Chondrosarcoma is a tumor of adulthood and older age. The majority of patients are older than 50 years of age at diagnosis, with a slight male predominance. The most common locations of involvement of chondrosarcoma include the bones of the axial skeleton (pelvis, scapula, sternum, and ribs) followed by the proximal femur and proximal humerus. Involvement of the hands and feet is rare. […] Primary central chondrosarcoma is the third most common primary malignancy of bone after myeloma and osteosarcoma.

• #21 Chondrosarcoma: Practice Essentials, Pathophysiology, Epidemiology

  https://emedicine.medscape.com/article/1258236-overview

  Conventional central chondrosarcomas account for nearly 80-90% of all chondrosarcomas and 20-27% of all primary bone sarcomas. They demonstrate a predilection for the axial skeleton. Rates of involvement are as follows: Pelvis and ribs, 45%; Ilium, 20%; Femur, 15%; Humerus, 10%; Others, 10%. The spine and the craniofacial bones are rarely involved. […] Chondrosarcomas are considerably rarer in children and adolescents than in adults.

• #22 Chondrosarcoma: Practice Essentials, Pathophysiology, Epidemiology

  https://emedicine.medscape.com/article/1258236-overview

  Conventional central chondrosarcomas account for nearly 80-90% of all chondrosarcomas and 20-27% of all primary bone sarcomas. They demonstrate a predilection for the axial skeleton. Rates of involvement are as follows: Pelvis and ribs, 45%; Ilium, 20%; Femur, 15%; Humerus, 10%; Others, 10%. The spine and the craniofacial bones are rarely involved. […] Chondrosarcomas are considerably rarer in children and adolescents than in adults.

• #23 Chondrosarcoma: Practice Essentials, Pathophysiology, Epidemiology

  https://emedicine.medscape.com/article/1258236-overview

  Conventional central chondrosarcomas account for nearly 80-90% of all chondrosarcomas and 20-27% of all primary bone sarcomas. They demonstrate a predilection for the axial skeleton. Rates of involvement are as follows: Pelvis and ribs, 45%; Ilium, 20%; Femur, 15%; Humerus, 10%; Others, 10%. The spine and the craniofacial bones are rarely involved. […] Chondrosarcomas are considerably rarer in children and adolescents than in adults.

• #24 Chondrosarcoma: Practice Essentials, Pathophysiology, Epidemiology

  https://emedicine.medscape.com/article/1258236-overview

  Conventional central chondrosarcomas account for nearly 80-90% of all chondrosarcomas and 20-27% of all primary bone sarcomas. They demonstrate a predilection for the axial skeleton. Rates of involvement are as follows: Pelvis and ribs, 45%; Ilium, 20%; Femur, 15%; Humerus, 10%; Others, 10%. The spine and the craniofacial bones are rarely involved. […] Chondrosarcomas are considerably rarer in children and adolescents than in adults.

• #25 Chondrosarcoma: Practice Essentials, Pathophysiology, Epidemiology

  https://emedicine.medscape.com/article/1258236-overview

  Conventional central chondrosarcomas account for nearly 80-90% of all chondrosarcomas and 20-27% of all primary bone sarcomas. They demonstrate a predilection for the axial skeleton. Rates of involvement are as follows: Pelvis and ribs, 45%; Ilium, 20%; Femur, 15%; Humerus, 10%; Others, 10%. The spine and the craniofacial bones are rarely involved. […] Chondrosarcomas are considerably rarer in children and adolescents than in adults.

• #26 Chondrosarcoma: Practice Essentials, Pathophysiology, Epidemiology

  https://emedicine.medscape.com/article/1258236-overview

  Conventional central chondrosarcomas account for nearly 80-90% of all chondrosarcomas and 20-27% of all primary bone sarcomas. They demonstrate a predilection for the axial skeleton. Rates of involvement are as follows: Pelvis and ribs, 45%; Ilium, 20%; Femur, 15%; Humerus, 10%; Others, 10%. The spine and the craniofacial bones are rarely involved. […] Chondrosarcomas are considerably rarer in children and adolescents than in adults.

• #27 Chondrosarcoma: Practice Essentials, Pathophysiology, Epidemiology

  https://emedicine.medscape.com/article/1258236-overview

  Conventional central chondrosarcomas account for nearly 80-90% of all chondrosarcomas and 20-27% of all primary bone sarcomas. They demonstrate a predilection for the axial skeleton. Rates of involvement are as follows: Pelvis and ribs, 45%; Ilium, 20%; Femur, 15%; Humerus, 10%; Others, 10%. The spine and the craniofacial bones are rarely involved. […] Chondrosarcomas are considerably rarer in children and adolescents than in adults.

• #28 Chondrosarcoma of the skull base – UpToDate

  https://www.uptodate.com/contents/chondrosarcoma-of-the-skull-base

  Chondrosarcomas of the skull base are rare tumors. They represent approximately 1 percent of chondrosarcomas and 0.15 percent of intracranial neoplasms. […] The majority are located in the middle cranial fossa and arise from within the spheno-petrosal, petro-occipital (petroclival), or spheno-occipital synchondroses. The most common locations are petrous bone (38 percent), clivus (24 percent), petroclival synchondrosis (20 percent), sphenoid bone (12 percent), and supra- or parasellar (7 percent). […] There is a predilection for the right skull base for reasons that are not known. Less commonly, chondrosarcomas in the nasal cavity secondarily involve the skull base and intracranial compartment. […] The median age at diagnosis is 43 years (range 18 to 85 years). There is a slight female predominance.

• #29 Chondrosarcoma | Springer Publishing

  https://connect.springerpub.com/content/book/978-0-8261-4853-7/part/part02/chapter/ch12

  Chondrosarcomas constitute a heterogeneous group of malignant cartilaginous matrix-producing bone neoplasms with diverse morphologic features and clinical behavior. Following osteosarcoma, chondrosarcoma is the second most common primary bone tumor, accounting for 20% to 27% of primary bone malignancy. […] Chondrosarcoma is poorly treatable because it is highly resistant to chemotherapy and radiation therapy. Surgical resection remains the „gold standard” for the treatment of localized chondrosarcoma. Owing to lack of effective treatment, the clinical management of advanced chondrosarcomas is exceptionally challenging. Future studies should further explore the utility of these candidate molecular targeted therapies in advanced chondrosarcoma patients.

• #30 Chondrosarcoma – UpToDate

  https://www.uptodate.com/contents/chondrosarcoma

  Chondrosarcomas are the third most common primary malignancy of bone after myeloma and osteosarcoma. They account for 20 to 27 percent of primary malignant osseous neoplasms. […] Conventional chondrosarcomas comprise a majority (90 percent) of all chondrosarcomas. […] High-grade chondrosarcomas are rare. These high-grade chondrosarcomas, along with other ultrarare variants, comprise approximately 5 to 10 percent of all chondrosarcomas. […] Histologic grade is one of the most important indicators of clinical behavior and prognosis.

• #31 Chondrosarcoma Workup: Laboratory Studies, Plain Radiography, Magnetic Resonance Imaging

  https://emedicine.medscape.com/article/1258236-workup

  Chondrosarcoma […] The National Comprehensive Cancer Network (NCCN) follows both the tumor-node-metastasis (TNM) classification of the American Joint Cancer Committee/Union for International Cancer Control (AJCC/UICC) and the Surgical Staging System from the Musculoskeletal Tumor Society (MTS) for staging. […] Table 1. Sex Ratios and Ages of Peak Incidence for Different Types of Chondrosarcoma […] Conventional […] Almost 1:1 (slight male predominance) […] 50-70 y (most common 50 y, gradual increase with age) […] Dedifferentiated […] Similar to the ratio above […] 50 y […] Clear cell […] 2.4:1 […] 20-40 y (common 10-90 y) […] Mesenchymal […] 1:1 […] 20-30 y (common in teenagers and young adults) […] Juxtacortical […] 1:1 […] 20-40 y

• #32

  https://www.orthobullets.com/pathology/8023/chondrosarcoma

  Chondrosarcoma is the second most common malignant primary bone tumor. These cancers are composed of malignant chondrocytes. There are various subtypes of chondrosarcoma, each with unique characteristics. „Conventional” chondrosarcoma accounts for 90% of chondrosarcomas and typically presents in adults over 40 with progressive pain. […] Epidemiology: Demographics (conventional chondrosarcoma) occurs in older adults (40 to 75 years), most 50 years. There is a slight male predominance. Specific subtypes of chondrosarcoma may present at younger ages. […] Anatomic location (conventional chondrosarcoma): most common locations include the pelvis (25% of all cases), proximal femur, distal femur, proximal humerus, distal tibia, and scapula. Rarely involves the spine or craniofacial bones. Typically metaphyseal or diaphyseal, rarely epiphyseal (except clear cell chondrosarcoma). Tumor location is important for diagnosis: cartilage tumors of the small bones of the hands and feet are mostly benign, whereas those of the flat bones (pelvis, scapula, ribs, sternum) are malignant until proven otherwise. Specific subtypes of chondrosarcoma have specific anatomic predilections.

• #33 Chondrosarcoma Epidemiology Forecasts, 2032: Focus on United States, EU4, (Germany, Spain, Italy, and France) United Kingdom, and Japan

  https://www.prnewswire.com/news-releases/chondrosarcoma-epidemiology-forecasts-2032-focus-on-united-states-eu4-germany-spain-italy-and-france-united-kingdom-and-japan-301850943.html

  Chondrosarcoma Epidemiology As the market is derived using a patient-based model, the Chondrosarcoma epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total incident cases of chondrosarcoma, primary chondrosarcoma cases, grade-specific cases of chondrosarcoma, mutation-specific cases of chondrosarcoma, stage-specific cases of conventional chondrosarcoma in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), United Kingdom, and Japan from 2019 to 2032. […] The total number of incident cases of chondrosarcoma in the United States was around 1,371 cases in 2022. […] The United States contributed to the largest incident population of chondrosarcoma, acquiring ~59% of the 7MM in 2022. Whereas EU4 and the UK, and Japan accounted for around 37% and 4% of the total population share, respectively, in 2022.

• #34 Chondrosarcoma – Epidemiology Forecast – 2032

  https://www.researchandmarkets.com/reports/5238582/chondrosarcoma-epidemiology-forecast-2032?srsltid=AfmBOopTFVTNWFjFLez9dKypoiD2kbfp8ntI3DNdLaAz8XD0Ukc_K-r_

  Chondrosarcoma is the most common primary bone cancer in adulthood and the second most common primary bone cancer overall, making up around 25% of all malignant bone cancer cases. […] The total incident cases of chondrosarcoma in the 7MM comprised approximately 2,300 cases in 2022 and are projected to increase during the forecasted period. […] The total number of incident cases of chondrosarcoma in the United States was around 1,371 cases in 2022. […] The United States contributed to the largest incident population of chondrosarcoma, acquiring ~59% of the 7MM in 2022. […] According to the estimates, in the United States, there were around 485, 584, 177, and 125 cases of Grade I, II, III, and IV, respectively, in 2022. […] Among the stage-specific rates of conventional chondrosarcoma, localized conventional chondrosarcoma accounted for approximately 75% of the patient share, while the rest of them were metastatic in nature. […] When it comes to disease progression, the rate is quite high in patients with high-grade conventional chondrosarcoma as compared to the ones with low-grade conventional chondrosarcoma.

• #35 Mesenchymal chondrosarcoma | Radiology Reference Article | Radiopaedia.org

  https://radiopaedia.org/articles/mesenchymal-chondrosarcoma?lang=us

  Mesenchymal chondrosarcomas are rare tumors and make up for ~2-4% of all chondrosarcomas. They occur in a wide age range and peak in the second and third decades of life. They are slightly more common in men. […] Mesenchymal chondrosarcomas are aggressive neoplasms with 5-year and 10-year survival rates ranging around ~60% and ~40%. Management includes complete resection combined with chemotherapy or radiotherapy. Young adults and children tend to have better outcomes as well as a craniofacial origin, whereas an axial origin and distant metastases at initial presentation are associated with a poorer prognosis. […] Complications include local recurrences and distant metastases, the latter can occur as late as 20 years after an initial presentation.

• #36 Mesenchymal chondrosarcoma metastatic – Overview of Information and Clinical Research

  https://clinicaltrials.eu/disease/mesenchymal-chondrosarcoma-metastatic/

  Mesenchymal chondrosarcoma (MCS) is a rare and aggressive subtype of chondrosarcoma, characterized by a high risk of distant metastases and poor prognosis. […] The rarity of this malignancy, accounting for about 5% of all chondrosarcoma cases, complicates the establishment of standardized treatment protocols. […] Due to the high risk of local recurrence and distant metastases, long-term surveillance is essential for managing MCS. […] This ongoing monitoring helps in early detection of recurrences and timely intervention.

• #37 Bone: Dedifferentiated chondrosarcoma

  https://atlasgeneticsoncology.org/solid-tumor/5337/bone-dedifferentiated-chondrosarcoma

  Dedifferentiated chondrosarcoma accounts for approximately 10% of all chondrosarcomas and shows an increased growth rate and rapid metastatic spread in comparison with ordinary chondrosarcomas. It arises most frequently in the 5th and 6th decade of life. Anatomically, the femur, pelvis and humerus are the most common sites of involvement. […] Clinical symptoms include pain, swelling, palpable tumor masses and a high rate (30%) of pathological fractures. Approximately 20% of patients have metastases at diagnosis. […] The average time from diagnosis to the onset of metastatic disease is usually short. The anatomical site of metastases is the lungs (70-82%), the viscera (20%) and the skeleton (10%). Histologically, metastases consist only of the high-grade anaplastic component. There is no uniform guideline for the treatment of metastases.

• #38 Periosteal Chondrosarcoma – SFA

  https://curesarcoma.org/sarcoma-subtypes/periosteal-chondrosarcoma/

  Periosteal chondrosarcoma is a rare chondrosarcoma subtype, representing about 2.5% of all chondrosarcomas. It has a peak incidence in the third decade of life, with a wide age range (9–79 years) and a male predominance. […] Periosteal chondrosarcomas have a relatively low metastatic rate (5–12.2%), with metastases especially involving the lungs and rarely the lymph nodes. Histological grading does not predict outcome.

• #39 Chondrosarcoma Workup: Laboratory Studies, Plain Radiography, Magnetic Resonance Imaging

  https://emedicine.medscape.com/article/1258236-workup

  Chondrosarcoma […] The National Comprehensive Cancer Network (NCCN) follows both the tumor-node-metastasis (TNM) classification of the American Joint Cancer Committee/Union for International Cancer Control (AJCC/UICC) and the Surgical Staging System from the Musculoskeletal Tumor Society (MTS) for staging. […] Table 1. Sex Ratios and Ages of Peak Incidence for Different Types of Chondrosarcoma […] Conventional […] Almost 1:1 (slight male predominance) […] 50-70 y (most common 50 y, gradual increase with age) […] Dedifferentiated […] Similar to the ratio above […] 50 y […] Clear cell […] 2.4:1 […] 20-40 y (common 10-90 y) […] Mesenchymal […] 1:1 […] 20-30 y (common in teenagers and young adults) […] Juxtacortical […] 1:1 […] 20-40 y

• #40 Chondrosarcoma epidemiology and demographics – wikidoc

  https://www.wikidoc.org/index.php/Chondrosarcoma_epidemiology_and_demographics

  Chondrosarcoma is the second most common malignant primary tumor of bone. It is most frequently diagnosed in patients in their 4th and 5th decades of life. Men are slightly more affected by chondrosarcoma than women. There is no racial predilection to chondrosarcoma. […] Chondrosarcoma is the second most common primary bone sarcoma. The incidence of chondrosarcoma is approximately 1 per 100,000 individuals worldwide. […] Chondrosarcoma is most frequently diagnosed in patients in their 4th and 5th decades of life. The average age at presentation is 51 years. […] There is no racial predilection to chondrosarcoma. […] Chondrosarcoma affects men and women almost equally with slight male predominance. Exception to this is the clear cell sub-type which has significant male preponderance. The male to female ratio is almost 1:1 except for clear cell chondrosarcoma it is 2.4:1.

• #41 Chondrosarcoma – NCI

  https://www.cancer.gov/pediatric-adult-rare-tumor/rare-tumors/rare-bone-tumors/chondrosarcoma

  CS is a rare type of bone tumor and affects 1 person per 200,000 per year in the US. It is more common in adults. […] Doctors estimate CS survival rates by how groups of people with CS have done in the past. Because there are so few CS patients, these rates may not be very accurate. […] The average 5-year survival rate for patients with CS is different depending on the subtype of CS the patient has. Different types of CS may grow more quickly or come back after the tumor is removed. In cases where the tumor grows back, called recurrence, or has spread to other parts of the body, the survival rate may be lower.

• #42 Epidemiology and Survivorship of Chondrosarcoma in the United States: An Analysis of the National Cancer Database | MDedge

  https://www.mdedge.com/fedprac/avaho/article/175095/mixed-topics/epidemiology-and-survivorship-chondrosarcoma-united-states

  Chondrosarcoma (CHS) is the second most common primary malignant solid bone tumor. This study summarizes descriptive epidemiologic and prognostic characteristics associated with CHS patients utilizing the National Cancer Database (NCDB). We identified 6,559 patients with CHS of the bone, joints, and/or articular cartilage in the NCDB from 2004-2015. Median age at diagnosis was 53 years. 53.3% of cases were in males, and 86.4% were in white patients. The most common NCDB analytic stage at presentation was stage I (60.5%). Overall probability of 5-year survival was 74.4%. The 5-year survival was much worse at stage IV compared to stages I, II, and III, as well as in dedifferentiated and mesenchymal tumor subtypes compared to conventional or other types of CHS. […] This study found CHS was most common in white patients, had a median age at diagnosis of 53 years, and was most frequently found in lower limb long bones and associated joints. In high grade tumors, perioperative chemotherapy did not improve survival compared to surgery alone.

• #43 Predictors of the survival of patients with chondrosarcoma of bone and metastatic disease at diagnosis

  https://www.jcancer.org/v10p2457.htm

  The demographic, prognostic, and outcome data of chondrosarcoma are well documented. […] Patients with chondrosarcoma and metastasis often have a poor prognosis. […] The 5-year survival rate for chondrosarcoma is 75.2%, which is much higher than that of osteosarcoma and Ewing sarcoma. […] The effects of radiotherapy and chemotherapy on chondrosarcoma are limited and surgical resection is still the mainstay of treatment. […] This study also assessed the prognostic utility of radiotherapy in primary chondrosarcoma of bone and metastasis at presentation. […] Our study is the first to describe the demographic information of such patients and explore possible predictors of survival using the SEER database. […] The 5- and 10-year OS rates of the metastatic chondrosarcoma were 28.4% and 22.8%, respectively, while the 5- and 10-year CSS rates were 31.2% and 26.6%.

• #44 Chondrosarcoma: Symptoms, Causes & Treatment

  https://my.clevelandclinic.org/health/diseases/22112-chondrosarcoma

  Chondrosarcomas are very rare, affecting 1 in 200,000 people in the U.S. You can develop a chondrosarcoma at any age, but the condition is more common in people ages 40 to 75, with most people receiving a diagnosis at age 51. […] Overall, 79% of people with chondrosarcoma are alive five years after diagnosis. […] Survival rates for chondrosarcoma vary depending on the tumor type and whether the tumor is spreading to other parts of your body. Overall, 79% of people with chondrosarcoma were alive five years after diagnosis. Here are specific survival rates based on tumor location: Local: Theres no sign of spreading from the bone where it started. 91% Regional: The tumor is spreading from your bone into nearby bones, tissues, organs or lymph nodes. 76% Distant: The tumor is in your lungs or in bones in other parts of your body. 17%

• #45 Chondrosarcoma patient characteristics, management, and outcomes based on over 5,000 cases from the National Cancer Database (NCDB) | PLOS One

  https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0268215

  Chondrosarcoma diagnosis was based on the International Classification of Diseases for Oncology, 3rd edition (ICD-O-3) using the histology codes 9220, 9221, 9243, 9240, and 9242. […] The cohort was distributed evenly across time periods, with approximately 1/3 of the cohort arising from each time period. […] Survival for the overall cohort was 90.38% at 1 year, 75.61% at 5 years and 64.18% at 10 years. […] The multivariate Cox analysis for the appendicular cohort revealed the likelihood of death to be significantly increased with age category and distant metastases at presentation. […] For the axial cohort, similar analysis revealed the likelihood of death to be significantly increased with increasing age category and distant metastases. […] Kaplan-Meier survival analysis showed the worst survival outcomes in the axial cohort and the best outcomes in the other group. […] Poor prognostic factors such as distant metastasis and axial involvement that hinder the means of surgical intervention have been shown to decrease long-term survival for patients.

• #46 Chondrosarcoma: Symptoms, Causes & Treatment

  https://my.clevelandclinic.org/health/diseases/22112-chondrosarcoma

  Chondrosarcomas are very rare, affecting 1 in 200,000 people in the U.S. You can develop a chondrosarcoma at any age, but the condition is more common in people ages 40 to 75, with most people receiving a diagnosis at age 51. […] Overall, 79% of people with chondrosarcoma are alive five years after diagnosis. […] Survival rates for chondrosarcoma vary depending on the tumor type and whether the tumor is spreading to other parts of your body. Overall, 79% of people with chondrosarcoma were alive five years after diagnosis. Here are specific survival rates based on tumor location: Local: Theres no sign of spreading from the bone where it started. 91% Regional: The tumor is spreading from your bone into nearby bones, tissues, organs or lymph nodes. 76% Distant: The tumor is in your lungs or in bones in other parts of your body. 17%

• #47 Chondrosarcoma: Symptoms, Causes & Treatment

  https://my.clevelandclinic.org/health/diseases/22112-chondrosarcoma

  Chondrosarcomas are very rare, affecting 1 in 200,000 people in the U.S. You can develop a chondrosarcoma at any age, but the condition is more common in people ages 40 to 75, with most people receiving a diagnosis at age 51. […] Overall, 79% of people with chondrosarcoma are alive five years after diagnosis. […] Survival rates for chondrosarcoma vary depending on the tumor type and whether the tumor is spreading to other parts of your body. Overall, 79% of people with chondrosarcoma were alive five years after diagnosis. Here are specific survival rates based on tumor location: Local: Theres no sign of spreading from the bone where it started. 91% Regional: The tumor is spreading from your bone into nearby bones, tissues, organs or lymph nodes. 76% Distant: The tumor is in your lungs or in bones in other parts of your body. 17%

• #48 Chondrosarcoma: Symptoms, Causes & Treatment

  https://my.clevelandclinic.org/health/diseases/22112-chondrosarcoma

  Chondrosarcomas are very rare, affecting 1 in 200,000 people in the U.S. You can develop a chondrosarcoma at any age, but the condition is more common in people ages 40 to 75, with most people receiving a diagnosis at age 51. […] Overall, 79% of people with chondrosarcoma are alive five years after diagnosis. […] Survival rates for chondrosarcoma vary depending on the tumor type and whether the tumor is spreading to other parts of your body. Overall, 79% of people with chondrosarcoma were alive five years after diagnosis. Here are specific survival rates based on tumor location: Local: Theres no sign of spreading from the bone where it started. 91% Regional: The tumor is spreading from your bone into nearby bones, tissues, organs or lymph nodes. 76% Distant: The tumor is in your lungs or in bones in other parts of your body. 17%

• #49 Chondrosarcoma: Symptoms, Causes & Treatment

  https://my.clevelandclinic.org/health/diseases/22112-chondrosarcoma

  Chondrosarcomas are very rare, affecting 1 in 200,000 people in the U.S. You can develop a chondrosarcoma at any age, but the condition is more common in people ages 40 to 75, with most people receiving a diagnosis at age 51. […] Overall, 79% of people with chondrosarcoma are alive five years after diagnosis. […] Survival rates for chondrosarcoma vary depending on the tumor type and whether the tumor is spreading to other parts of your body. Overall, 79% of people with chondrosarcoma were alive five years after diagnosis. Here are specific survival rates based on tumor location: Local: Theres no sign of spreading from the bone where it started. 91% Regional: The tumor is spreading from your bone into nearby bones, tissues, organs or lymph nodes. 76% Distant: The tumor is in your lungs or in bones in other parts of your body. 17%

• #50 Predictors of the survival of patients with chondrosarcoma of bone and metastatic disease at diagnosis

  https://www.jcancer.org/v10p2457.htm

  The demographic, prognostic, and outcome data of chondrosarcoma are well documented. […] Patients with chondrosarcoma and metastasis often have a poor prognosis. […] The 5-year survival rate for chondrosarcoma is 75.2%, which is much higher than that of osteosarcoma and Ewing sarcoma. […] The effects of radiotherapy and chemotherapy on chondrosarcoma are limited and surgical resection is still the mainstay of treatment. […] This study also assessed the prognostic utility of radiotherapy in primary chondrosarcoma of bone and metastasis at presentation. […] Our study is the first to describe the demographic information of such patients and explore possible predictors of survival using the SEER database. […] The 5- and 10-year OS rates of the metastatic chondrosarcoma were 28.4% and 22.8%, respectively, while the 5- and 10-year CSS rates were 31.2% and 26.6%.

• #51 Chondrosarcoma – UpToDate

  https://www.uptodate.com/contents/chondrosarcoma

  Chondrosarcomas are the third most common primary malignancy of bone after myeloma and osteosarcoma. They account for 20 to 27 percent of primary malignant osseous neoplasms. […] Conventional chondrosarcomas comprise a majority (90 percent) of all chondrosarcomas. […] High-grade chondrosarcomas are rare. These high-grade chondrosarcomas, along with other ultrarare variants, comprise approximately 5 to 10 percent of all chondrosarcomas. […] Histologic grade is one of the most important indicators of clinical behavior and prognosis.

• #52 Chondrosarcoma – UpToDate

  https://www.uptodate.com/contents/chondrosarcoma

  Chondrosarcomas are the third most common primary malignancy of bone after myeloma and osteosarcoma. They account for 20 to 27 percent of primary malignant osseous neoplasms. […] Conventional chondrosarcomas comprise a majority (90 percent) of all chondrosarcomas. […] High-grade chondrosarcomas are rare. These high-grade chondrosarcomas, along with other ultrarare variants, comprise approximately 5 to 10 percent of all chondrosarcomas. […] Histologic grade is one of the most important indicators of clinical behavior and prognosis.

• #53 Prognostic factors and outcomes of osseous chondrosarcoma after surgery: the 2004–2014 Surveillance, Epidemiology, and End Results database study – Chen – Translational Cancer Research

  https://tcr.amegroups.org/article/view/20233/html

  Chondrosarcoma is a major malignant tumor occurs at skeletal system, the prognostic factors and survival outcomes of osseous chondrosarcoma after surgery were still unclear. […] The demographic information extracted include: age, gender, race, year of diagnosis, tumor sites, tumor size, grade, stages from the Surveillance, Epidemiology, and End Results (SEER) 18 registries research database [20042014]. […] We find grade, stage were independent prognostic factors for survival rate of osseous chondrosarcoma after surgery, and higher age more than 75 years, bigger tumor size more than 20 cm is also predicted poor outcomes. […] The Multivariable Cox proportional hazard regression models find the factors of gender, race and tumor sites have no significant associated with the CCSS. However, the grades of moderately differentiated, poorly differentiated and undifferentiated have poorer outcomes when the well differentiated osseous chondrosarcoma used as reference, with HR (95% CI) of 2.57 (1.464.53) and 5.36 (2.919.85), respectively. The stages of regional and metastasis also have poorer outcomes when the localized osseous chondrosarcoma used as reference, with HR (95% CI) of 2.35 (1.314.24) and 11.17 (5.5922.32), respectively. […] We found grade, stage are independent prognostic factors for survival rate of osseous chondrosarcoma after surgery, and higher age more than 75 years, bigger tumor size more than 20 cm is also predicted poor outcomes.

• #54 Prognostic factors and outcomes of osseous chondrosarcoma after surgery: the 2004–2014 Surveillance, Epidemiology, and End Results database study – Chen – Translational Cancer Research

  https://tcr.amegroups.org/article/view/20233/html

  Chondrosarcoma is a major malignant tumor occurs at skeletal system, the prognostic factors and survival outcomes of osseous chondrosarcoma after surgery were still unclear. […] The demographic information extracted include: age, gender, race, year of diagnosis, tumor sites, tumor size, grade, stages from the Surveillance, Epidemiology, and End Results (SEER) 18 registries research database [20042014]. […] We find grade, stage were independent prognostic factors for survival rate of osseous chondrosarcoma after surgery, and higher age more than 75 years, bigger tumor size more than 20 cm is also predicted poor outcomes. […] The Multivariable Cox proportional hazard regression models find the factors of gender, race and tumor sites have no significant associated with the CCSS. However, the grades of moderately differentiated, poorly differentiated and undifferentiated have poorer outcomes when the well differentiated osseous chondrosarcoma used as reference, with HR (95% CI) of 2.57 (1.464.53) and 5.36 (2.919.85), respectively. The stages of regional and metastasis also have poorer outcomes when the localized osseous chondrosarcoma used as reference, with HR (95% CI) of 2.35 (1.314.24) and 11.17 (5.5922.32), respectively. […] We found grade, stage are independent prognostic factors for survival rate of osseous chondrosarcoma after surgery, and higher age more than 75 years, bigger tumor size more than 20 cm is also predicted poor outcomes.

• #55 Prognostic factors and outcomes of osseous chondrosarcoma after surgery: the 2004–2014 Surveillance, Epidemiology, and End Results database study – Chen – Translational Cancer Research

  https://tcr.amegroups.org/article/view/20233/html

  Chondrosarcoma is a major malignant tumor occurs at skeletal system, the prognostic factors and survival outcomes of osseous chondrosarcoma after surgery were still unclear. […] The demographic information extracted include: age, gender, race, year of diagnosis, tumor sites, tumor size, grade, stages from the Surveillance, Epidemiology, and End Results (SEER) 18 registries research database [20042014]. […] We find grade, stage were independent prognostic factors for survival rate of osseous chondrosarcoma after surgery, and higher age more than 75 years, bigger tumor size more than 20 cm is also predicted poor outcomes. […] The Multivariable Cox proportional hazard regression models find the factors of gender, race and tumor sites have no significant associated with the CCSS. However, the grades of moderately differentiated, poorly differentiated and undifferentiated have poorer outcomes when the well differentiated osseous chondrosarcoma used as reference, with HR (95% CI) of 2.57 (1.464.53) and 5.36 (2.919.85), respectively. The stages of regional and metastasis also have poorer outcomes when the localized osseous chondrosarcoma used as reference, with HR (95% CI) of 2.35 (1.314.24) and 11.17 (5.5922.32), respectively. […] We found grade, stage are independent prognostic factors for survival rate of osseous chondrosarcoma after surgery, and higher age more than 75 years, bigger tumor size more than 20 cm is also predicted poor outcomes.

• #56 Prognostic factors and outcomes of osseous chondrosarcoma after surgery: the 2004–2014 Surveillance, Epidemiology, and End Results database study – Chen – Translational Cancer Research

  https://tcr.amegroups.org/article/view/20233/html

  Chondrosarcoma is a major malignant tumor occurs at skeletal system, the prognostic factors and survival outcomes of osseous chondrosarcoma after surgery were still unclear. […] The demographic information extracted include: age, gender, race, year of diagnosis, tumor sites, tumor size, grade, stages from the Surveillance, Epidemiology, and End Results (SEER) 18 registries research database [20042014]. […] We find grade, stage were independent prognostic factors for survival rate of osseous chondrosarcoma after surgery, and higher age more than 75 years, bigger tumor size more than 20 cm is also predicted poor outcomes. […] The Multivariable Cox proportional hazard regression models find the factors of gender, race and tumor sites have no significant associated with the CCSS. However, the grades of moderately differentiated, poorly differentiated and undifferentiated have poorer outcomes when the well differentiated osseous chondrosarcoma used as reference, with HR (95% CI) of 2.57 (1.464.53) and 5.36 (2.919.85), respectively. The stages of regional and metastasis also have poorer outcomes when the localized osseous chondrosarcoma used as reference, with HR (95% CI) of 2.35 (1.314.24) and 11.17 (5.5922.32), respectively. […] We found grade, stage are independent prognostic factors for survival rate of osseous chondrosarcoma after surgery, and higher age more than 75 years, bigger tumor size more than 20 cm is also predicted poor outcomes.

• #57 Prognostic factors and outcomes of osseous chondrosarcoma after surgery: the 2004–2014 Surveillance, Epidemiology, and End Results database study – Chen – Translational Cancer Research

  https://tcr.amegroups.org/article/view/20233/html

  Chondrosarcoma is a major malignant tumor occurs at skeletal system, the prognostic factors and survival outcomes of osseous chondrosarcoma after surgery were still unclear. […] The demographic information extracted include: age, gender, race, year of diagnosis, tumor sites, tumor size, grade, stages from the Surveillance, Epidemiology, and End Results (SEER) 18 registries research database [20042014]. […] We find grade, stage were independent prognostic factors for survival rate of osseous chondrosarcoma after surgery, and higher age more than 75 years, bigger tumor size more than 20 cm is also predicted poor outcomes. […] The Multivariable Cox proportional hazard regression models find the factors of gender, race and tumor sites have no significant associated with the CCSS. However, the grades of moderately differentiated, poorly differentiated and undifferentiated have poorer outcomes when the well differentiated osseous chondrosarcoma used as reference, with HR (95% CI) of 2.57 (1.464.53) and 5.36 (2.919.85), respectively. The stages of regional and metastasis also have poorer outcomes when the localized osseous chondrosarcoma used as reference, with HR (95% CI) of 2.35 (1.314.24) and 11.17 (5.5922.32), respectively. […] We found grade, stage are independent prognostic factors for survival rate of osseous chondrosarcoma after surgery, and higher age more than 75 years, bigger tumor size more than 20 cm is also predicted poor outcomes.

• #58 Predictors of the survival of patients with chondrosarcoma of bone and metastatic disease at diagnosis

  https://www.jcancer.org/v10p2457.htm

  Because of the dismal survival of this patient population, it is necessary to explore prognostic factors to better guide the management of such patients. […] Tumor grade was usually recognized as a very important predictor of chondrosarcoma. […] Therefore, tumor grade is an important prognostic factor for chondrosarcoma patients with metastasis, whether at presentation or otherwise. […] In our cohort, tumor size 10 cm was an independent predictor of both OS and CSS. […] Surgical excision is considered as the standard treatment for chondrosarcoma, but little is known regarding the standard treatment of patients with primary chondrosarcoma of bone and metastasis at presentation. […] In patients with metastasis, removing the primary tumor can alleviate pain, improve quality of life, and prolong survival.

• #59 Treatment method and prognostic factors of chondrosarcoma: based on Surveillance, Epidemiology, and End Results (SEER) database – Hua – Translational Cancer Research

  https://tcr.amegroups.org/article/view/41253/html

  Chondrosarcoma is a malignant tumor originating from cartilage tissue. It is the second most malignant bone tumor, accounting for about 10% to 15% of all primary bone tumors. […] So far, there have been no reports of large-scale clinical statistics on the relationship between non-surgical treatment and prognosis in patients with chondrosarcoma. […] The annual incidence of about 200,000 people, accounting for about 20% of bone malignant tumor in the United States. […] In order to solve the problem of insufficient clinical data, we collected information on patients with chondrosarcoma from the Surveillance, Epidemiology, and End Results (SEER) database managed by the National Cancer Institute. […] This study found that although non-surgical treatment of chondrosarcoma has made great progress, at present, it is still not considered that non-surgical treatment can significantly improve the prognosis. There are many factors affecting the prognosis of chondrosarcoma, including age, primary site, histological type, grade, tumor size, distant metastasis and treatment method. […] The results showed age, primary site, histological type, grade, tumor size, metastasis, and treatment method were independent factors affecting ACM and CSSM.

• #60 Bone: Dedifferentiated chondrosarcoma

  https://atlasgeneticsoncology.org/solid-tumor/5337/bone-dedifferentiated-chondrosarcoma

  Metastatic disease at presentation is a strong negative predictive factor of patient survival. Tumor location at the pelvis has been reported as an independent risk factor for metastases and death. Local recurrence and the histology of the dedifferentiated component have also been noted to be independent risk factors for metastases and death.

• #61 Epidemiology and Survivorship of Chondrosarcoma in the United States: An Analysis of the National Cancer Database | MDedge

  https://community.the-hospitalist.org/content/epidemiology-and-survivorship-chondrosarcoma-united-states-analysis-national-cancer-database

  Chondrosarcoma (CHS) is the second most common primary malignant solid bone tumor. […] This study summarizes descriptive epidemiologic and prognostic characteristics associated with CHS patients utilizing the National Cancer Database (NCDB). […] We identified 6,559 patients with CHS of the bone, joints, and/or articular cartilage in the NCDB from 2004-2015. […] Median age at diagnosis was 53 years. 53.3% of cases were in males, and 86.4% were in white patients. […] The most common NCDB analytic stage at presentation was stage I (60.5%). […] Overall probability of 5-year survival was 74.4%. […] The dedifferentiated subtype of CHS had the poorest 5-year survival (25.4%), while juxtacortical had the highest (93.4%). […] This study found CHS was most common in white patients, had a median age at diagnosis of 53 years, and was most frequently found in lower limb long bones and associated joints. […] The 5-year survival was much worse at stage IV compared to stages I, II, and III, as well as in dedifferentiated and mesenchymal tumor subtypes compared to conventional or other types of CHS. […] In high grade tumors, perioperative chemotherapy did not improve survival compared to surgery alone.

• #62 Predictors of the survival of patients with chondrosarcoma of bone and metastatic disease at diagnosis

  https://www.jcancer.org/v10p2457.htm

  Because of the dismal survival of this patient population, it is necessary to explore prognostic factors to better guide the management of such patients. […] Tumor grade was usually recognized as a very important predictor of chondrosarcoma. […] Therefore, tumor grade is an important prognostic factor for chondrosarcoma patients with metastasis, whether at presentation or otherwise. […] In our cohort, tumor size 10 cm was an independent predictor of both OS and CSS. […] Surgical excision is considered as the standard treatment for chondrosarcoma, but little is known regarding the standard treatment of patients with primary chondrosarcoma of bone and metastasis at presentation. […] In patients with metastasis, removing the primary tumor can alleviate pain, improve quality of life, and prolong survival.

• #63 Bone: Dedifferentiated chondrosarcoma

  https://atlasgeneticsoncology.org/solid-tumor/5337/bone-dedifferentiated-chondrosarcoma

  Metastatic disease at presentation is a strong negative predictive factor of patient survival. Tumor location at the pelvis has been reported as an independent risk factor for metastases and death. Local recurrence and the histology of the dedifferentiated component have also been noted to be independent risk factors for metastases and death.

• #64 Risk analysis of pulmonary metastasis of chondrosarcoma by establishing and validating a new clinical prediction model: a clinical study based on SEER database | BMC Musculoskeletal Disorders | Full Text

  https://bmcmusculoskeletdisord.biomedcentral.com/articles/10.1186/s12891-021-04414-2

  The prognosis of lung metastasis (LM) in patients with chondrosarcoma was poor. […] According to previous research, approximately 8 to 38% of the patients with chondrosarcoma developed distant metastasis and lung was the preferred site of metastasis. […] The occurrence of LM had a strong predictor of poor prognosis. […] Therefore, it was imperative to identify the risk factors of chondrosarcoma patients with lung metastasis. […] The Surveillance, Epidemiology, and End Results (SEER) database that sponsored by the National Cancer Institute records cancer incidence and survival data from 18 population-based cancer registries. […] The purpose of this study is to construct a nomogram to evaluate high-risk group of chondrosarcoma patients with LM due to the importance of LM in the prognosis of chondrosarcoma patients.

• #65 Risk analysis of pulmonary metastasis of chondrosarcoma by establishing and validating a new clinical prediction model: a clinical study based on SEER database | BMC Musculoskeletal Disorders | Full Text

  https://bmcmusculoskeletdisord.biomedcentral.com/articles/10.1186/s12891-021-04414-2

  The prognosis of lung metastasis (LM) in patients with chondrosarcoma was poor. […] According to previous research, approximately 8 to 38% of the patients with chondrosarcoma developed distant metastasis and lung was the preferred site of metastasis. […] The occurrence of LM had a strong predictor of poor prognosis. […] Therefore, it was imperative to identify the risk factors of chondrosarcoma patients with lung metastasis. […] The Surveillance, Epidemiology, and End Results (SEER) database that sponsored by the National Cancer Institute records cancer incidence and survival data from 18 population-based cancer registries. […] The purpose of this study is to construct a nomogram to evaluate high-risk group of chondrosarcoma patients with LM due to the importance of LM in the prognosis of chondrosarcoma patients.

• #66

  https://journals.lww.com/md-journal/fulltext/2023/09150/risk_factors_for_distant_metastasis_of.72.aspx

  Chondrosarcoma is the second largest bone malignancy after osteosarcoma and mainly affects middle-aged adults, where patients with distant metastasis (DM) often have a poor prognosis. […] Data on patients diagnosed with chondrosarcoma from 2004 to 2015 were obtained from the Surveillance, Epidemiology, and End Results database. […] A total of 1870 chondrosarcoma patients were included in the study after data screening, of which 157 patients (8.40%) had DM at the time of diagnosis. […] Univariate and multivariate logistic regression analysis screened four independent risk factors, including grade, tumor number, T stage, and N stage. […] The current study screened for independent risk factors for DM from chondrosarcoma, which will help clinicians evaluate patients. […] According to related studies, about 8% of chondrosarcoma patients have DM at the time of diagnosis. […] The current study included new data and the current data was larger and found the incidence of DM to be 8.40% and identified four important predictors of DM in chondrosarcoma patients: serial number, grade, T stage, and N stage.

• #67 Periosteal Chondrosarcoma – SFA

  https://curesarcoma.org/sarcoma-subtypes/periosteal-chondrosarcoma/

  Periosteal chondrosarcoma is a rare chondrosarcoma subtype, representing about 2.5% of all chondrosarcomas. It has a peak incidence in the third decade of life, with a wide age range (9–79 years) and a male predominance. […] Periosteal chondrosarcomas have a relatively low metastatic rate (5–12.2%), with metastases especially involving the lungs and rarely the lymph nodes. Histological grading does not predict outcome.

• #68

  https://journals.lww.com/ijsoncology/abstract/2020/05000/impact_of_nodal_involvement_on_survival_outcomes.9.aspx

  Factors associated with nodal involvement in chondrosarcoma and outcomes based on treatment modality were analyzed using the Surveillance, Epidemiology, and End Results (SEER) database. […] Synchronous regional nodal metastases were present in 1.3% of chondrosarcoma patients. Lymph node involvement was associated with primary tumor location in extraskeletal tissue and the pelvis, and with distant metastasis and larger primary tumor size at diagnosis. […] The nodal disease is uncommon at presentation in chondrosarcoma. Greater clinical vigilance for regional nodal metastases may be warranted for those with specific risk factors, including extraskeletal or pelvic primary sites, myxoid, mesenchymal, or dedifferentiated histologies, and large size. Surgical excision of regional nodes is associated with improved DSS/OS. This analysis suggests a therapeutic effect of surgical treatment, rather than selection for favorable underlying biological factors.

• #69

  https://journals.lww.com/md-journal/fulltext/2023/09150/risk_factors_for_distant_metastasis_of.72.aspx

  Chondrosarcoma is the second largest bone malignancy after osteosarcoma and mainly affects middle-aged adults, where patients with distant metastasis (DM) often have a poor prognosis. […] Data on patients diagnosed with chondrosarcoma from 2004 to 2015 were obtained from the Surveillance, Epidemiology, and End Results database. […] A total of 1870 chondrosarcoma patients were included in the study after data screening, of which 157 patients (8.40%) had DM at the time of diagnosis. […] Univariate and multivariate logistic regression analysis screened four independent risk factors, including grade, tumor number, T stage, and N stage. […] The current study screened for independent risk factors for DM from chondrosarcoma, which will help clinicians evaluate patients. […] According to related studies, about 8% of chondrosarcoma patients have DM at the time of diagnosis. […] The current study included new data and the current data was larger and found the incidence of DM to be 8.40% and identified four important predictors of DM in chondrosarcoma patients: serial number, grade, T stage, and N stage.

• #70

  https://journals.lww.com/md-journal/fulltext/2023/09150/risk_factors_for_distant_metastasis_of.72.aspx

  Chondrosarcoma is the second largest bone malignancy after osteosarcoma and mainly affects middle-aged adults, where patients with distant metastasis (DM) often have a poor prognosis. […] Data on patients diagnosed with chondrosarcoma from 2004 to 2015 were obtained from the Surveillance, Epidemiology, and End Results database. […] A total of 1870 chondrosarcoma patients were included in the study after data screening, of which 157 patients (8.40%) had DM at the time of diagnosis. […] Univariate and multivariate logistic regression analysis screened four independent risk factors, including grade, tumor number, T stage, and N stage. […] The current study screened for independent risk factors for DM from chondrosarcoma, which will help clinicians evaluate patients. […] According to related studies, about 8% of chondrosarcoma patients have DM at the time of diagnosis. […] The current study included new data and the current data was larger and found the incidence of DM to be 8.40% and identified four important predictors of DM in chondrosarcoma patients: serial number, grade, T stage, and N stage.

• #71

  https://journals.lww.com/md-journal/fulltext/2023/09150/risk_factors_for_distant_metastasis_of.72.aspx

  Chondrosarcoma is the second largest bone malignancy after osteosarcoma and mainly affects middle-aged adults, where patients with distant metastasis (DM) often have a poor prognosis. […] Data on patients diagnosed with chondrosarcoma from 2004 to 2015 were obtained from the Surveillance, Epidemiology, and End Results database. […] A total of 1870 chondrosarcoma patients were included in the study after data screening, of which 157 patients (8.40%) had DM at the time of diagnosis. […] Univariate and multivariate logistic regression analysis screened four independent risk factors, including grade, tumor number, T stage, and N stage. […] The current study screened for independent risk factors for DM from chondrosarcoma, which will help clinicians evaluate patients. […] According to related studies, about 8% of chondrosarcoma patients have DM at the time of diagnosis. […] The current study included new data and the current data was larger and found the incidence of DM to be 8.40% and identified four important predictors of DM in chondrosarcoma patients: serial number, grade, T stage, and N stage.

• #72

  https://journals.lww.com/md-journal/fulltext/2023/09150/risk_factors_for_distant_metastasis_of.72.aspx

  Chondrosarcoma is the second largest bone malignancy after osteosarcoma and mainly affects middle-aged adults, where patients with distant metastasis (DM) often have a poor prognosis. […] Data on patients diagnosed with chondrosarcoma from 2004 to 2015 were obtained from the Surveillance, Epidemiology, and End Results database. […] A total of 1870 chondrosarcoma patients were included in the study after data screening, of which 157 patients (8.40%) had DM at the time of diagnosis. […] Univariate and multivariate logistic regression analysis screened four independent risk factors, including grade, tumor number, T stage, and N stage. […] The current study screened for independent risk factors for DM from chondrosarcoma, which will help clinicians evaluate patients. […] According to related studies, about 8% of chondrosarcoma patients have DM at the time of diagnosis. […] The current study included new data and the current data was larger and found the incidence of DM to be 8.40% and identified four important predictors of DM in chondrosarcoma patients: serial number, grade, T stage, and N stage.

• #73

  https://journals.lww.com/md-journal/fulltext/2023/09150/risk_factors_for_distant_metastasis_of.72.aspx

  Chondrosarcoma is the second largest bone malignancy after osteosarcoma and mainly affects middle-aged adults, where patients with distant metastasis (DM) often have a poor prognosis. […] Data on patients diagnosed with chondrosarcoma from 2004 to 2015 were obtained from the Surveillance, Epidemiology, and End Results database. […] A total of 1870 chondrosarcoma patients were included in the study after data screening, of which 157 patients (8.40%) had DM at the time of diagnosis. […] Univariate and multivariate logistic regression analysis screened four independent risk factors, including grade, tumor number, T stage, and N stage. […] The current study screened for independent risk factors for DM from chondrosarcoma, which will help clinicians evaluate patients. […] According to related studies, about 8% of chondrosarcoma patients have DM at the time of diagnosis. […] The current study included new data and the current data was larger and found the incidence of DM to be 8.40% and identified four important predictors of DM in chondrosarcoma patients: serial number, grade, T stage, and N stage.

• #74 Risk analysis of pulmonary metastasis of chondrosarcoma by establishing and validating a new clinical prediction model: a clinical study based on SEER database | BMC Musculoskeletal Disorders | Full Text

  https://bmcmusculoskeletdisord.biomedcentral.com/articles/10.1186/s12891-021-04414-2

  This study, we found that the following five independent risk factors including gender, age at the diagnosis, marital status, tumor size, and the lymph node involvement, were identified to be associated with LM applying univariate and multivariable logistic regression analysis on the data collected from the SEER database. […] The poor prognosis of patients with chondrosarcoma might be associated with the lung metastasis. […] Therefore, we intended to identify risk factors of chondrosarcoma patients with lung metastasis. […] The visual nomogram is well known for its predictive accuracy and has made remarkable contributions to modern medical decision-making. […] Generally speaking, regional lymph node metastasis developed quite rarely in chondrosarcoma, and the incidence was approximately 1.3% across all chondrosarcoma.

• #75 Risk analysis of pulmonary metastasis of chondrosarcoma by establishing and validating a new clinical prediction model: a clinical study based on SEER database | BMC Musculoskeletal Disorders | Full Text

  https://bmcmusculoskeletdisord.biomedcentral.com/articles/10.1186/s12891-021-04414-2

  This study, we found that the following five independent risk factors including gender, age at the diagnosis, marital status, tumor size, and the lymph node involvement, were identified to be associated with LM applying univariate and multivariable logistic regression analysis on the data collected from the SEER database. […] The poor prognosis of patients with chondrosarcoma might be associated with the lung metastasis. […] Therefore, we intended to identify risk factors of chondrosarcoma patients with lung metastasis. […] The visual nomogram is well known for its predictive accuracy and has made remarkable contributions to modern medical decision-making. […] Generally speaking, regional lymph node metastasis developed quite rarely in chondrosarcoma, and the incidence was approximately 1.3% across all chondrosarcoma.

• #76 Risk analysis of pulmonary metastasis of chondrosarcoma by establishing and validating a new clinical prediction model: a clinical study based on SEER database | BMC Musculoskeletal Disorders | Full Text

  https://bmcmusculoskeletdisord.biomedcentral.com/articles/10.1186/s12891-021-04414-2

  This study, we found that the following five independent risk factors including gender, age at the diagnosis, marital status, tumor size, and the lymph node involvement, were identified to be associated with LM applying univariate and multivariable logistic regression analysis on the data collected from the SEER database. […] The poor prognosis of patients with chondrosarcoma might be associated with the lung metastasis. […] Therefore, we intended to identify risk factors of chondrosarcoma patients with lung metastasis. […] The visual nomogram is well known for its predictive accuracy and has made remarkable contributions to modern medical decision-making. […] Generally speaking, regional lymph node metastasis developed quite rarely in chondrosarcoma, and the incidence was approximately 1.3% across all chondrosarcoma.

• #77 Risk analysis of pulmonary metastasis of chondrosarcoma by establishing and validating a new clinical prediction model: a clinical study based on SEER database | BMC Musculoskeletal Disorders | Full Text

  https://bmcmusculoskeletdisord.biomedcentral.com/articles/10.1186/s12891-021-04414-2

  This study, we found that the following five independent risk factors including gender, age at the diagnosis, marital status, tumor size, and the lymph node involvement, were identified to be associated with LM applying univariate and multivariable logistic regression analysis on the data collected from the SEER database. […] The poor prognosis of patients with chondrosarcoma might be associated with the lung metastasis. […] Therefore, we intended to identify risk factors of chondrosarcoma patients with lung metastasis. […] The visual nomogram is well known for its predictive accuracy and has made remarkable contributions to modern medical decision-making. […] Generally speaking, regional lymph node metastasis developed quite rarely in chondrosarcoma, and the incidence was approximately 1.3% across all chondrosarcoma.

• #78 Risk analysis of pulmonary metastasis of chondrosarcoma by establishing and validating a new clinical prediction model: a clinical study based on SEER database | BMC Musculoskeletal Disorders | Full Text

  https://bmcmusculoskeletdisord.biomedcentral.com/articles/10.1186/s12891-021-04414-2

  This study, we found that the following five independent risk factors including gender, age at the diagnosis, marital status, tumor size, and the lymph node involvement, were identified to be associated with LM applying univariate and multivariable logistic regression analysis on the data collected from the SEER database. […] The poor prognosis of patients with chondrosarcoma might be associated with the lung metastasis. […] Therefore, we intended to identify risk factors of chondrosarcoma patients with lung metastasis. […] The visual nomogram is well known for its predictive accuracy and has made remarkable contributions to modern medical decision-making. […] Generally speaking, regional lymph node metastasis developed quite rarely in chondrosarcoma, and the incidence was approximately 1.3% across all chondrosarcoma.

• #79 Risk analysis of pulmonary metastasis of chondrosarcoma by establishing and validating a new clinical prediction model: a clinical study based on SEER database | BMC Musculoskeletal Disorders | Full Text

  https://bmcmusculoskeletdisord.biomedcentral.com/articles/10.1186/s12891-021-04414-2

  This study, we found that the following five independent risk factors including gender, age at the diagnosis, marital status, tumor size, and the lymph node involvement, were identified to be associated with LM applying univariate and multivariable logistic regression analysis on the data collected from the SEER database. […] The poor prognosis of patients with chondrosarcoma might be associated with the lung metastasis. […] Therefore, we intended to identify risk factors of chondrosarcoma patients with lung metastasis. […] The visual nomogram is well known for its predictive accuracy and has made remarkable contributions to modern medical decision-making. […] Generally speaking, regional lymph node metastasis developed quite rarely in chondrosarcoma, and the incidence was approximately 1.3% across all chondrosarcoma.

• #80 Bone: Dedifferentiated chondrosarcoma

  https://atlasgeneticsoncology.org/solid-tumor/5337/bone-dedifferentiated-chondrosarcoma

  Dedifferentiated chondrosarcoma accounts for approximately 10% of all chondrosarcomas and shows an increased growth rate and rapid metastatic spread in comparison with ordinary chondrosarcomas. It arises most frequently in the 5th and 6th decade of life. Anatomically, the femur, pelvis and humerus are the most common sites of involvement. […] Clinical symptoms include pain, swelling, palpable tumor masses and a high rate (30%) of pathological fractures. Approximately 20% of patients have metastases at diagnosis. […] The average time from diagnosis to the onset of metastatic disease is usually short. The anatomical site of metastases is the lungs (70-82%), the viscera (20%) and the skeleton (10%). Histologically, metastases consist only of the high-grade anaplastic component. There is no uniform guideline for the treatment of metastases.

• #81 Mesenchymal chondrosarcoma metastatic – Overview of Information and Clinical Research

  https://clinicaltrials.eu/disease/mesenchymal-chondrosarcoma-metastatic/

  Mesenchymal chondrosarcoma (MCS) is a rare and aggressive subtype of chondrosarcoma, characterized by a high risk of distant metastases and poor prognosis. […] The rarity of this malignancy, accounting for about 5% of all chondrosarcoma cases, complicates the establishment of standardized treatment protocols. […] Due to the high risk of local recurrence and distant metastases, long-term surveillance is essential for managing MCS. […] This ongoing monitoring helps in early detection of recurrences and timely intervention.

• #82 Identifying consensus and areas for future research in chondrosarcoma | Bone & Joint

  https://boneandjoint.org.uk/Article/10.1302/0301-620X.107B2.BJJ-2024-0643.R1

  The Birmingham Orthopaedic Oncology Meeting (BOOM), held in January 2024, convened 309 delegates from 53 countries to discuss and refine 21 consensus statements on the optimal management of chondrosarcoma. […] Strong (80%) consensus was achieved on 19 out of 21 statements, reflecting agreement among delegates. Key areas of consensus included the role of radiology in diagnosis and surveillance, the management of locally recurrent disease, and the treatment of dedifferentiated chondrosarcoma. Notably, there was agreement that routine chemotherapy has no role in chondrosarcoma treatment, and radiological surveillance is safe for intraosseous chondrosarcomas. […] The Birmingham Orthopaedic Oncology Meeting (BOOM) successfully achieved strong consensus (80%) on 19 out of 21 statements regarding chondrosarcoma management, reflecting global agreement on critical aspects such as radiological diagnosis, surveillance, and the treatment of dedifferentiated chondrosarcoma.

• #83 Identifying consensus and areas for future research in chondrosarcoma | Bone & Joint

  https://boneandjoint.org.uk/Article/10.1302/0301-620X.107B2.BJJ-2024-0643.R1

  Despite the consensus, ongoing controversies, particularly related to the treatment of atypical cartilage tumours and surgical margins, highlight the need for further research and international collaboration within the orthopaedic oncology community. […] Chondrosarcoma surveillance should be stratified by high- and low-risk protocols. Minimum imaging includes radiographs of the chest and affected area. In high-risk patients an MRI of the surgical site and a CT chest could be considered (91% super majority strong consensus). […] Limited evidence suggests that the risk of metastatic disease from atypical chondroid tumour (ACT) is very low and radiological surveillance for ACTs is safe in the medium term, but no protocols exist for the duration or interval of follow-up (92% super majority strong consensus).

• #84 Identifying consensus and areas for future research in chondrosarcoma | Bone & Joint

  https://boneandjoint.org.uk/Article/10.1302/0301-620X.107B2.BJJ-2024-0643.R1

  Despite the consensus, ongoing controversies, particularly related to the treatment of atypical cartilage tumours and surgical margins, highlight the need for further research and international collaboration within the orthopaedic oncology community. […] Chondrosarcoma surveillance should be stratified by high- and low-risk protocols. Minimum imaging includes radiographs of the chest and affected area. In high-risk patients an MRI of the surgical site and a CT chest could be considered (91% super majority strong consensus). […] Limited evidence suggests that the risk of metastatic disease from atypical chondroid tumour (ACT) is very low and radiological surveillance for ACTs is safe in the medium term, but no protocols exist for the duration or interval of follow-up (92% super majority strong consensus).

• #85 Identifying consensus and areas for future research in chondrosarcoma | Bone & Joint

  https://boneandjoint.org.uk/Article/10.1302/0301-620X.107B2.BJJ-2024-0643.R1

  Despite the consensus, ongoing controversies, particularly related to the treatment of atypical cartilage tumours and surgical margins, highlight the need for further research and international collaboration within the orthopaedic oncology community. […] Chondrosarcoma surveillance should be stratified by high- and low-risk protocols. Minimum imaging includes radiographs of the chest and affected area. In high-risk patients an MRI of the surgical site and a CT chest could be considered (91% super majority strong consensus). […] Limited evidence suggests that the risk of metastatic disease from atypical chondroid tumour (ACT) is very low and radiological surveillance for ACTs is safe in the medium term, but no protocols exist for the duration or interval of follow-up (92% super majority strong consensus).

• #86 Chondrosarcoma

  https://www.massgeneral.org/orthopaedics/oncology/conditions-and-treatments/chondrosarcoma

  Chondrosarcoma is a malignant cartilage producing tumor of bone, the second most common after osteosarcoma. […] Surveillance: After the initial postop visits (typically at 2 and 6 weeks), routine surveillance is for 10 years with imaging: […] Annual visit thereafter for 5 more years, which concludes the surveillance standard of care of 10 years (but most patients like to continue with an annual visit).

• #87 Mesenchymal chondrosarcoma | Radiology Reference Article | Radiopaedia.org

  https://radiopaedia.org/articles/mesenchymal-chondrosarcoma?lang=us

  Mesenchymal chondrosarcomas are rare tumors and make up for ~2-4% of all chondrosarcomas. They occur in a wide age range and peak in the second and third decades of life. They are slightly more common in men. […] Mesenchymal chondrosarcomas are aggressive neoplasms with 5-year and 10-year survival rates ranging around ~60% and ~40%. Management includes complete resection combined with chemotherapy or radiotherapy. Young adults and children tend to have better outcomes as well as a craniofacial origin, whereas an axial origin and distant metastases at initial presentation are associated with a poorer prognosis. […] Complications include local recurrences and distant metastases, the latter can occur as late as 20 years after an initial presentation.

• #88 Orbital Mesenchymal Chondrosarcoma – EyeWiki

  https://eyewiki.org/Orbital_Mesenchymal_Chondrosarcoma

  Mesenchymal chondrosarcoma accounts for 2-3% of all chondrosarcomas. A third of mesenchymal chondrosarcomas occur extra-skeletally, and of these, the orbit is the third most common site of this neoplasm after the meninges and lower extremities (Alkatan 2018). […] Patients with orbital mesenchymal chondrosarcoma tend to be younger than patients with chondrosarcoma in other sites (Hererra 2012). It most commonly occurs in the second or third decades, however, outliers include several cases in children (Alkatan 2018) and one in an elderly, 84 year old female (Shimo-Oku 1980). Orbital mesenchymal chondrosarcoma is thought to be more common in women (Alkatan 2018, Murphey 2003). […] The prognosis for mesenchymal chondrosarcoma is poor and unpredictable (Duane 1985). The all site survival rate is 55% at 5 years (Hererra 2012). It has a long term survival of approximately 30% (Jacobs 1994). This may be partly due to the fact that it has a tendency to recur late and can have delayed distant metastasis (Odashiro 2009). However, orbital lesions have a higher survival rate than lesions in other sites. Indeed some patients may have complete tumor response and long term survival. Nonetheless, the tumor can recur or metastasize even 20 years after treatment, thus long-term monitoring in addition to early detection is essential (Hererra 2012, Alkatan 2018).

• #89 Identifying consensus and areas for future research in chondrosarcoma | Bone & Joint

  https://boneandjoint.org.uk/Article/10.1302/0301-620X.107B2.BJJ-2024-0643.R1

  Despite the consensus, ongoing controversies, particularly related to the treatment of atypical cartilage tumours and surgical margins, highlight the need for further research and international collaboration within the orthopaedic oncology community. […] Chondrosarcoma surveillance should be stratified by high- and low-risk protocols. Minimum imaging includes radiographs of the chest and affected area. In high-risk patients an MRI of the surgical site and a CT chest could be considered (91% super majority strong consensus). […] Limited evidence suggests that the risk of metastatic disease from atypical chondroid tumour (ACT) is very low and radiological surveillance for ACTs is safe in the medium term, but no protocols exist for the duration or interval of follow-up (92% super majority strong consensus).

• #90 Treating Chondrosarcoma with Urgency and Compassion – CS Foundation | CS Foundation

  https://csfshayna.org/site/treating-chondrosarcoma-with-urgency-and-compassion/

  Chondrosarcoma is a rare bone and soft tissue cancer that has no established treatment protocol especially for high grade Conventional Chondrosarcoma and Dedifferentiated Chondrosarcoma. […] Early diagnosis and detection of this cancer is also lacking. Many patients suffering from Chondrosarcoma are misdiagnosed and given misinformation. […] Chondrosarcoma is rare compared to other cancers effecting an average of 600 patients each year in the United States. […] The article is also a message to the oncology community that there is a lot of work that needs to be done to find viable treatment options for Chondrosarcoma. […] Better surveillance algorithms are needed, particularly including full body imaging, and especially with regards to periods of remission, and to screen for usual and unusual sites of metastasis.

• #91 Treating Chondrosarcoma with Urgency and Compassion – CS Foundation | CS Foundation

  https://csfshayna.org/site/treating-chondrosarcoma-with-urgency-and-compassion/

  Early diagnosis and better detection are vital in the treatment of Chondrosarcoma and that would include full body scans to confirm detection of masses. […] Research funding specifically targeting maintenance of remission interventions is urgently needed. […] There is essentially no research on interventions to maintain remission. […] A national expert recommendation defending routine use of whole-body scans, later supported by evidence-based recommendations, should help improve obtaining permissions and getting insurance coverage. […] The unusual aggressiveness and atypical metastatic distribution suggests atypical phenotypes of conventional chondrosarcoma exists. Additional research is needed to define these unusual phenotypes. […] No centralized clinical parameters exist for chondrosarcoma. […] An international patient registry (or sub-registry of an existing cancer registry) including genetic data, donated tissue, and clinical information can be utilized by researchers. […] Treatment and care on all levels need to be compassionate, act with urgency and be patient specific.

• #92 Chondrosarcoma: A Clinical Review

  https://pmc.ncbi.nlm.nih.gov/articles/PMC10095313/

  Prompt diagnosis and treatment has the potential to reduce the disease burden and may help reduce the risk of metastatic spread and thus improve survival. At present, there are no novel detection methods that have been proven to improve early diagnosis. However, circulating tumor DNA has emerged as a potential promising biomarker to aid in both the diagnosis and residual disease detection in a range of tumors. In chondrosarcoma, isocitrate dehydrogenase (IDH) mutations are commonly found, and early studies suggest serum IDH DNA can be detected in patients with chondrosarcoma. More research is needed to validate potential biomarkers and to determine their clinical utility in detecting chondrosarcoma at an early stage.

• #93 Treating Chondrosarcoma with Urgency and Compassion – CS Foundation | CS Foundation

  https://csfshayna.org/site/treating-chondrosarcoma-with-urgency-and-compassion/

  Early diagnosis and better detection are vital in the treatment of Chondrosarcoma and that would include full body scans to confirm detection of masses. […] Research funding specifically targeting maintenance of remission interventions is urgently needed. […] There is essentially no research on interventions to maintain remission. […] A national expert recommendation defending routine use of whole-body scans, later supported by evidence-based recommendations, should help improve obtaining permissions and getting insurance coverage. […] The unusual aggressiveness and atypical metastatic distribution suggests atypical phenotypes of conventional chondrosarcoma exists. Additional research is needed to define these unusual phenotypes. […] No centralized clinical parameters exist for chondrosarcoma. […] An international patient registry (or sub-registry of an existing cancer registry) including genetic data, donated tissue, and clinical information can be utilized by researchers. […] Treatment and care on all levels need to be compassionate, act with urgency and be patient specific.

• #94 Will INBX-109 Launch Change Chondrosarcoma Treatment Space?

  https://www.delveinsight.com/blog/chondrosarcoma-treatment

  Chondrosarcoma is a group of bone tumors made up of cells that make too much cartilage. As per DelveInsight analysis, the total incident cases of chondrosarcoma in the 7MM comprised approximately 2,331 cases in 2022 and are projected to increase during the forecasted period. Our estimates suggest that the United States had the highest incidence rate of chondrosarcoma among the seven major markets, with ~1,300 reported cases in 2022. […] Chondrosarcomas rarity presents challenges for conducting clinical trials and understanding the epidemiology. Limited outcome data for locally advanced or metastatic patients highlights the need for new chondrosarcoma treatment options. […] The scarcity of epidemiological studies on chondrosarcoma makes it difficult to develop evidence-based prevention and management strategies due to limited data on the diseases prevalence, incidence, risk factors, and outcomes. Thus, more research is necessary to improve our understanding of this rare disease and improve patient diagnosis and chondrosarcoma treatment outcomes.

• #95 Chondrosarcoma Epidemiology Forecasts, 2032: Focus on United States, EU4, (Germany, Spain, Italy, and France) United Kingdom, and Japan

  https://www.prnewswire.com/news-releases/chondrosarcoma-epidemiology-forecasts-2032-focus-on-united-states-eu4-germany-spain-italy-and-france-united-kingdom-and-japan-301850943.html

  Chondrosarcoma Epidemiology As the market is derived using a patient-based model, the Chondrosarcoma epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total incident cases of chondrosarcoma, primary chondrosarcoma cases, grade-specific cases of chondrosarcoma, mutation-specific cases of chondrosarcoma, stage-specific cases of conventional chondrosarcoma in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), United Kingdom, and Japan from 2019 to 2032. […] The total number of incident cases of chondrosarcoma in the United States was around 1,371 cases in 2022. […] The United States contributed to the largest incident population of chondrosarcoma, acquiring ~59% of the 7MM in 2022. Whereas EU4 and the UK, and Japan accounted for around 37% and 4% of the total population share, respectively, in 2022.

• #96 Chondrosarcoma Epidemiology Forecasts, 2032: Focus on United States, EU4, (Germany, Spain, Italy, and France) United Kingdom, and Japan

  https://www.prnewswire.com/news-releases/chondrosarcoma-epidemiology-forecasts-2032-focus-on-united-states-eu4-germany-spain-italy-and-france-united-kingdom-and-japan-301850943.html

  Among the EU4 countries, France accounted for the largest number of Chondrosarcoma cases, followed by Germany, whereas Spain accounted for the lowest number of cases in 2022. […] According to the publisher estimates, in the United States, there were around 485, 584, 177, and 125 cases of Grade I, II, III, and IV, respectively, in 2022. […] The total incident cases of chondrosarcoma in the 7MM comprised approximately 2,300 cases in 2022 and are projected to increase during the forecasted period.

• #97 Chondrosarcoma | Bone Cancer Research Trust

  https://www.bcrt.org.uk/information/information-by-type/chondrosarcoma/

  Chondrosarcoma is the most common primary bone cancer in adulthood, and the second most common primary bone cancer overall. It makes up around 25% of all malignant bone cancer cases. […] In the UK there are around 190 new cases of chondrosarcoma diagnosed each year. In The Republic of Ireland there are around 12 new cases of chondrosarcoma diagnosed each year. […] The incidence rate in England is around 2.9 people affected per 1 million people of the population. […] Chondrosarcoma is the most common form of primary bone cancer affecting all age groups. […] 80% of cases are in people aged 40 years or older.

• #98 The Epidemiology of Chondrosarcoma in Iran Based on Iran National Cancer Registry

  https://brieflands.com/articles/ijcm-119308

  The age-specific incidence rate of chondrosarcoma and its 3 more prevalent subtypes, conventional, myxoid, and mesenchymal, per million person-years among the Iranian population are shown in Table 3. […] The ASIR of chondrosarcoma varies between 1 and 3 per million people in different countries. […] The ASIR of chondrosarcoma was slightly higher in males (1.73 in 1 million people) than females (1.27 in 1 million people). […] The mean age of patients in our study was 44.08 at the time of diagnosis, which is considerably less compared to studies in Norway, the USA, and the Netherlands, wherein the mean age at the time of diagnosis was above 50 years. […] Higher mortality of chondrosarcoma in Iran indicates a need for better case-finding and follow-up of patients with chondrosarcoma in Iran as timely diagnosis and proper care may improve the patient’s outcomes and survival.

• #99 The Epidemiology of Chondrosarcoma in Iran Based on Iran National Cancer Registry

  https://brieflands.com/articles/ijcm-119308

  The age-specific incidence rate of chondrosarcoma and its 3 more prevalent subtypes, conventional, myxoid, and mesenchymal, per million person-years among the Iranian population are shown in Table 3. […] The ASIR of chondrosarcoma varies between 1 and 3 per million people in different countries. […] The ASIR of chondrosarcoma was slightly higher in males (1.73 in 1 million people) than females (1.27 in 1 million people). […] The mean age of patients in our study was 44.08 at the time of diagnosis, which is considerably less compared to studies in Norway, the USA, and the Netherlands, wherein the mean age at the time of diagnosis was above 50 years. […] Higher mortality of chondrosarcoma in Iran indicates a need for better case-finding and follow-up of patients with chondrosarcoma in Iran as timely diagnosis and proper care may improve the patient’s outcomes and survival.

• #100 The Epidemiology of Chondrosarcoma in Iran Based on Iran National Cancer Registry

  https://brieflands.com/articles/ijcm-119308

  The age-specific incidence rate of chondrosarcoma and its 3 more prevalent subtypes, conventional, myxoid, and mesenchymal, per million person-years among the Iranian population are shown in Table 3. […] The ASIR of chondrosarcoma varies between 1 and 3 per million people in different countries. […] The ASIR of chondrosarcoma was slightly higher in males (1.73 in 1 million people) than females (1.27 in 1 million people). […] The mean age of patients in our study was 44.08 at the time of diagnosis, which is considerably less compared to studies in Norway, the USA, and the Netherlands, wherein the mean age at the time of diagnosis was above 50 years. […] Higher mortality of chondrosarcoma in Iran indicates a need for better case-finding and follow-up of patients with chondrosarcoma in Iran as timely diagnosis and proper care may improve the patient’s outcomes and survival.

• #101 Risk analysis of pulmonary metastasis of chondrosarcoma by establishing and validating a new clinical prediction model: a clinical study based on SEER database | BMC Musculoskeletal Disorders | Full Text

  https://bmcmusculoskeletdisord.biomedcentral.com/articles/10.1186/s12891-021-04414-2

  The prognosis of lung metastasis (LM) in patients with chondrosarcoma was poor. […] According to previous research, approximately 8 to 38% of the patients with chondrosarcoma developed distant metastasis and lung was the preferred site of metastasis. […] The occurrence of LM had a strong predictor of poor prognosis. […] Therefore, it was imperative to identify the risk factors of chondrosarcoma patients with lung metastasis. […] The Surveillance, Epidemiology, and End Results (SEER) database that sponsored by the National Cancer Institute records cancer incidence and survival data from 18 population-based cancer registries. […] The purpose of this study is to construct a nomogram to evaluate high-risk group of chondrosarcoma patients with LM due to the importance of LM in the prognosis of chondrosarcoma patients.

• #102 Novel prognostication of patients with spinal and pelvic chondrosarcoma using deep survival neural networks | BMC Medical Informatics and Decision Making | Full Text

  https://bmcmedinformdecismak.biomedcentral.com/articles/10.1186/s12911-019-1008-4

  We used the Surveillance, Epidemiology, and End Results (SEER) database to develop and validate deep survival neural network machine learning (ML) algorithms to predict survival following a spino-pelvic chondrosarcoma diagnosis. […] The Surveillance, Epidemiology, and End Results (SEER) database has been queried in a series of reports to analyze all primary malignant tumors of the osseous spine, including chondrosarcoma. […] The SEER registry has been collecting cancer-related information since 1973, and it represents 28% of the total U.S. population today, serving as the only population-based comprehensive data source, including stage of cancer, treatment modality and survival data. […] Previous investigations have analyzed survival period of patients from the SEER database based on demographics and prognostic determinants of primary osseous neoplasms of the spine.

• #103 Chondrosarcoma of the Osseous Spine

  https://escholarship.org/uc/item/1m70q36n

  To determine the epidemiology and prognostic indicators in patients with chondrosarcoma of the osseous spine. […] Chondrosarcoma of the spine is rare, with limited data on its epidemiology, clinicopathologic features, and treatment outcomes. […] The Surveillance, Epidemiology, and End Results Registry was queried for patients with chondrosarcoma of the osseous spine from 1973 to 2012. […] The search identified 973 cases of spinal chondrosarcoma. […] Surgical resection confers survival benefit in patients with chondrosarcoma of the spine independent of extent of disease. […] Radiotherapy improves survival in patients with metastatic disease and worsens outcomes in patients with confined and locally invasive disease.

• #104 Chondrosarcoma of the Osseous Spine

  https://escholarship.org/uc/item/1m70q36n

  To determine the epidemiology and prognostic indicators in patients with chondrosarcoma of the osseous spine. […] Chondrosarcoma of the spine is rare, with limited data on its epidemiology, clinicopathologic features, and treatment outcomes. […] The Surveillance, Epidemiology, and End Results Registry was queried for patients with chondrosarcoma of the osseous spine from 1973 to 2012. […] The search identified 973 cases of spinal chondrosarcoma. […] Surgical resection confers survival benefit in patients with chondrosarcoma of the spine independent of extent of disease. […] Radiotherapy improves survival in patients with metastatic disease and worsens outcomes in patients with confined and locally invasive disease.

• #105 Risk analysis of pulmonary metastasis of chondrosarcoma by establishing and validating a new clinical prediction model: a clinical study based on SEER database | BMC Musculoskeletal Disorders | Full Text

  https://bmcmusculoskeletdisord.biomedcentral.com/articles/10.1186/s12891-021-04414-2

  The prognosis of lung metastasis (LM) in patients with chondrosarcoma was poor. […] According to previous research, approximately 8 to 38% of the patients with chondrosarcoma developed distant metastasis and lung was the preferred site of metastasis. […] The occurrence of LM had a strong predictor of poor prognosis. […] Therefore, it was imperative to identify the risk factors of chondrosarcoma patients with lung metastasis. […] The Surveillance, Epidemiology, and End Results (SEER) database that sponsored by the National Cancer Institute records cancer incidence and survival data from 18 population-based cancer registries. […] The purpose of this study is to construct a nomogram to evaluate high-risk group of chondrosarcoma patients with LM due to the importance of LM in the prognosis of chondrosarcoma patients.

• #106

  https://journals.lww.com/ijsoncology/abstract/2020/05000/impact_of_nodal_involvement_on_survival_outcomes.9.aspx

  Factors associated with nodal involvement in chondrosarcoma and outcomes based on treatment modality were analyzed using the Surveillance, Epidemiology, and End Results (SEER) database. […] Synchronous regional nodal metastases were present in 1.3% of chondrosarcoma patients. Lymph node involvement was associated with primary tumor location in extraskeletal tissue and the pelvis, and with distant metastasis and larger primary tumor size at diagnosis. […] The nodal disease is uncommon at presentation in chondrosarcoma. Greater clinical vigilance for regional nodal metastases may be warranted for those with specific risk factors, including extraskeletal or pelvic primary sites, myxoid, mesenchymal, or dedifferentiated histologies, and large size. Surgical excision of regional nodes is associated with improved DSS/OS. This analysis suggests a therapeutic effect of surgical treatment, rather than selection for favorable underlying biological factors.

• #107 Prognostic factors and outcomes of osseous chondrosarcoma after surgery: the 2004–2014 Surveillance, Epidemiology, and End Results database study – Chen – Translational Cancer Research

  https://tcr.amegroups.org/article/view/20233/html

  Chondrosarcoma is a major malignant tumor occurs at skeletal system, the prognostic factors and survival outcomes of osseous chondrosarcoma after surgery were still unclear. […] The demographic information extracted include: age, gender, race, year of diagnosis, tumor sites, tumor size, grade, stages from the Surveillance, Epidemiology, and End Results (SEER) 18 registries research database [20042014]. […] We find grade, stage were independent prognostic factors for survival rate of osseous chondrosarcoma after surgery, and higher age more than 75 years, bigger tumor size more than 20 cm is also predicted poor outcomes. […] The Multivariable Cox proportional hazard regression models find the factors of gender, race and tumor sites have no significant associated with the CCSS. However, the grades of moderately differentiated, poorly differentiated and undifferentiated have poorer outcomes when the well differentiated osseous chondrosarcoma used as reference, with HR (95% CI) of 2.57 (1.464.53) and 5.36 (2.919.85), respectively. The stages of regional and metastasis also have poorer outcomes when the localized osseous chondrosarcoma used as reference, with HR (95% CI) of 2.35 (1.314.24) and 11.17 (5.5922.32), respectively. […] We found grade, stage are independent prognostic factors for survival rate of osseous chondrosarcoma after surgery, and higher age more than 75 years, bigger tumor size more than 20 cm is also predicted poor outcomes.

• #108 Epidemiology and Survivorship of Chondrosarcoma in the United States: An Analysis of the National Cancer Database | MDedge

  https://community.the-hospitalist.org/content/epidemiology-and-survivorship-chondrosarcoma-united-states-analysis-national-cancer-database

  Chondrosarcoma (CHS) is the second most common primary malignant solid bone tumor. […] This study summarizes descriptive epidemiologic and prognostic characteristics associated with CHS patients utilizing the National Cancer Database (NCDB). […] We identified 6,559 patients with CHS of the bone, joints, and/or articular cartilage in the NCDB from 2004-2015. […] Median age at diagnosis was 53 years. 53.3% of cases were in males, and 86.4% were in white patients. […] The most common NCDB analytic stage at presentation was stage I (60.5%). […] Overall probability of 5-year survival was 74.4%. […] The dedifferentiated subtype of CHS had the poorest 5-year survival (25.4%), while juxtacortical had the highest (93.4%). […] This study found CHS was most common in white patients, had a median age at diagnosis of 53 years, and was most frequently found in lower limb long bones and associated joints. […] The 5-year survival was much worse at stage IV compared to stages I, II, and III, as well as in dedifferentiated and mesenchymal tumor subtypes compared to conventional or other types of CHS. […] In high grade tumors, perioperative chemotherapy did not improve survival compared to surgery alone.

• #109 DARWIN EU® – Chondrosarcoma: patient demographics, treatments, and survival in the period 2010-2023 | HMA-EMA Catalogues of real-world data sources and studies

  https://catalogues.ema.europa.eu/node/4063/methodological-aspects

  The study population will include all individuals with a first diagnosis of chondrosarcoma identified in each database between 01/01/2010 and 31/12/2023. […] To describe demographics, treatments, and overall survival of patients with incident chondrosarcoma, stratified by age, sex, study period, country/database, and, if available, by AJCC/UICC TNM stage categories and histological grade in 2010-2023. […] To estimate the overall survival of newly diagnosed chondrosarcoma patients during the study period (2010-2023).

• #110 Risk analysis of pulmonary metastasis of chondrosarcoma by establishing and validating a new clinical prediction model: a clinical study based on SEER database | BMC Musculoskeletal Disorders | Full Text

  https://bmcmusculoskeletdisord.biomedcentral.com/articles/10.1186/s12891-021-04414-2

  According to the results of logistic regression analysis, taking patients without lymph node metastasis as the baseline, the risk ratios of lung metastasis for patients with lymph node involvement (OR=27.164) and patients with unknown lymph node metastasis (OR=8.027) were 27.164 and 8.027 respectively. […] The tumor size was associated with the risk for developing lung metastasis according to the statistical results acquired from univariate and multivariable logistic regression. […] Besides, the older patients with chondrosarcoma had a higher tendency developed with LM and had more negative prognosis conforming to the result of logistic regression. […] In addition, the result of logistic regression revealed males had a higher risk than females developing LM. […] It was worth noting that this study considered the marital status as a risk factor on LM. […] In summary, we constructed a novel nomogram to predict risk factors for chondrosarcoma patients developing LM, including sex, age, tumor size, marital status and tumor size based on epidemiological characteristics obtained from the SEER database.

• #111 Novel prognostication of patients with spinal and pelvic chondrosarcoma using deep survival neural networks | BMC Medical Informatics and Decision Making | Full Text

  https://bmcmedinformdecismak.biomedcentral.com/articles/10.1186/s12911-019-1008-4

  The SEER database enables outcome analysis for a large number of patients based on attributes that are broadly classified as demographics (e.g., age, sex, location), therapeutic (e.g., surgical procedure, radiation therapy), and outcomes (e.g., survival period, cause of death). […] In this study, we developed a novel algorithm specific to survival analysis, and the results indicate it offers better performance compared to those in other studies using both a conventional statistical model and an ML model. […] RED_SNN is a valid method to predict survival for spinal and pelvic chondrosarcoma, and it appears to be comparable to other methods.

• #112 Mice with Trp53 and Rb1 deficiency in chondrocytes spontaneously develop chondrosarcoma via overactivation of YAP signaling | Cell Death & Disease

  https://www.nature.com/articles/s41419-022-04916-4

  Chondrosarcoma (CHS) is a rare type of soft sarcoma with increased production of cartilage matrix arising from soft bone tissues. Currently, surgical resection is the primary clinical treatment for chondrosarcoma due to the poor response to radiotherapy and chemotherapy. However, the therapeutic effect is not satisfactory due to the higher local recurrence rate. Thus, management and elucidation of the pathological mechanism of chondrosarcoma remain an ongoing challenge, and the development of effective chondrosarcoma mouse models and treatment options are urgently needed. […] Chondrosarcoma is a rare type of primary bone cartilage malignancy with an incident rate of about two new cases per a million populations per year. It is the second most common primary malignant bone tumor and has a higher local recurrence rate. Although most solid tumors have infrequent metastasis, lung metastasis is the most common in chondrosarcoma.

• #113 Mice with Trp53 and Rb1 deficiency in chondrocytes spontaneously develop chondrosarcoma via overactivation of YAP signaling | Cell Death & Disease

  https://www.nature.com/articles/s41419-022-04916-4

  The identification of some tumor suppressors mutations in cancer tissues can provide new strategies and options for the development of the new drug targets. Among these tumor suppressors, the mutations of Trp53 and Rb1 are most well-studied in different tumors. Notably, alterations of Trp53 and Rb1 were observed in about 33-96% and 20-50% of chondrosarcomas, respectively. […] Our results showed that Trp53 and Rb1 deficiency in chondrocytes caused chondrosarcoma with serious disruption in the vertebrate bone and lung metastasis. […] Overall, we first demonstrated that loss of Trp53 and Rb1 in chondrocytes caused spinal chondrosarcoma and lung metastasis, and the inhibition of YAP expression and activity may be therapeutically valuable. […] The incidence of spinal chondrosarcomas in humans is about 212%, and the thoracic spine is the most frequent localization, followed by the cervical and lumbar region.

• #114 Mice with Trp53 and Rb1 deficiency in chondrocytes spontaneously develop chondrosarcoma via overactivation of YAP signaling | Cell Death & Disease

  https://www.nature.com/articles/s41419-022-04916-4

  The identification of some tumor suppressors mutations in cancer tissues can provide new strategies and options for the development of the new drug targets. Among these tumor suppressors, the mutations of Trp53 and Rb1 are most well-studied in different tumors. Notably, alterations of Trp53 and Rb1 were observed in about 33-96% and 20-50% of chondrosarcomas, respectively. […] Our results showed that Trp53 and Rb1 deficiency in chondrocytes caused chondrosarcoma with serious disruption in the vertebrate bone and lung metastasis. […] Overall, we first demonstrated that loss of Trp53 and Rb1 in chondrocytes caused spinal chondrosarcoma and lung metastasis, and the inhibition of YAP expression and activity may be therapeutically valuable. […] The incidence of spinal chondrosarcomas in humans is about 212%, and the thoracic spine is the most frequent localization, followed by the cervical and lumbar region.

Zobacz więcej